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Background 
My research interest is focused on autosomal dominant polycystic kidney disease (ADPKD). ADPKD is the 
most common hereditary cause of end-stage renal disease (ESRD), affecting more than 4.5 Mio worldwide and 
more than 10’000 patients in Switzerland. ADPKD is caused by mutations in the polycystic kidney disease 1 
gene (PKD1) or in the polycystic kidney disease gene 2 (PKD2). The protein products of these two genes, 
polycystin-1 (PC-1) and polycystin-2 (PC-2) are expressed on renal tubular epithelial cells (TECs), specifically 
by the cilia of these cells. The polycystin complexes on cilia function as sensors of the extracellular environment 
and elicit intracellular responses through phosphorylation pathways. The disease characterized by the 
progressive development of innumerable cysts in both kidneys, which distort the normal kidney architecture and 
leads to a loss of renal function. Currently there is no therapy available. 
 
As a physician-scientist I work at the interface between the research laboratory and patient care. My hope is that 
such a translational research and medicine change the outcome of this serious disease. 
 
Basic science research 
The basic research science group is located at the University Zurich –Irchel within the Physiological Institute 
and the Zurich Center for Integrative Human Physiology (ZIHP). Group members are Ming Wu and Shagun 
Raina, both PhD students and Claudia Wuhrmann, technical assistant. Former member is Patricia Wahl, PhD. 
 
Sirolimus treatment slows rodent polycystic kidney disease progression 
In ADPKD renal cysts are lined by a single layer of cells originating from the epithelia of the nephrons. These 
tubular epithelial cells (TECs) have an increased proliferation rate. The mammalian target of Rapamycin 
(mTOR) is a key intermediary kinase in multiple mitogenic signalling pathways and plays a central role in 
modulating cellular proliferation, cell growth processes and angiogenesis. Activated mTOR directly 
phosphorylates p70S6 protein kinase (S6K) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1) which 
promotes cell growth through an increase in translation. Rapamycin (sirolimus; Rapamune®) and its analogue 
everolimus (Certican®) are macrocyclic lactones that bind to FKBP-12, thereby inhibiting specifically mTOR 
kinase activity. Both drugs are clinically used as immunosuppressive agents and exhibit well-known anti-
proliferative effects. Several rodent models for ADPKD exist, whereas the Han:SPRD Cy/+ rat has emerged as 
an excellent ADPKD model which closely resembles the human disease. Heterozygous male Han:SPRD rats 
with the Pkdr1 gene mutation (Cy/+) develop a slowly progressing polycystic kidney disease (PKD). To test our 
hypothesis that the inhibition of the mTOR pathway will slow polycystic kidney disease progression, we 
examined the effect of sirolimus on cyst growth and renal function loss in the Han:SPRD rat model [1]. The 
expression and phosphorylation of the downstream effector of the mTOR pathway, S6K was also analyzed. The 
oral administration of sirolimus through the drinking water for 3 months reduced indeed cyst volume and the 
steady increase in BUN and creatinine in male Cy/+ rats. A relatively low sirolimus blood level of 0.5 to 1.9 µg/l 
effectively reduced 2-kidney/total body weight (2K/TBW) and cyst volume density (CVD) by 36% and 18%, 
respectively. Western blot analysis from wild type Han:SPRD rat and treated and untreated Cy/+ rat kidneys for 
total amount and phosphorylated S6K showed that the mTOR pathway is not expressed in normal adult kidneys 
but in untreated Cy/+. Sirolimus effectively reduced phosphorylation at Thr389 and Thr421/Ser424 of S6K in 
Cy/+ kidneys and that correlated well with the histomorphometric findings. Our findings pointed to an important 
role of the mTOR pathway in the pathogenesis of cyst growth.  
 
Akt/mTOR/S6K pathway is upregulated in polycystic kidney disease 
Because the Akt kinase is an upstream regulator of mTOR, we hypothesized that the activity of Akt could be 
enhanced in the kidneys of Han:SPRD rats. The primary pathway by which growth factors and cytokines activate 
mTOR and its downstream targets is via the PI3K/Akt pathway. Growth factors stimulate phosphatidylinositol 3-
kinase (PI3K) activating Akt via phosphorylation on two residues (Ser473 and Thr308) which in turn activates 
mTOR. Renal cyst fluid from PKD mice and rodent models contain epidermal growth factor (EGF)-like peptides 
in mitogenic concentration and treatment with EGFR tyrosine kinase inhibitor attenuated disease progression in 
Han:SPRD rats. We therefore analyzed the Akt expression on RNA and protein level as well in the tissue by 
immunohistochemistry of polycystic rat kidneys [2]. Western blotting and enzyme-linked immunosorbent assay 
showed a significant increase in phosphorylated Akt in Cy/+ compared to wild type kidneys. 
Immunohistochemistry revealed that phosphorylated Akt is highly expressed in mitotic cells, beginning with the 
onset of the prophase. Staining by bromo-deoxyuridine (BrdU) and cell cycle marker Ki67 demonstrated a 6 to 
9-fold higher rate of proliferation of TECs lining cysts compared to normal tubules. Our study showed that Akt 
is instrumental in mitosis in TECs of normal and cystic tubules. Furthermore, by examining the distribution of 
pS6K(Thr421/Ser424) with immunofluorescence, we could show that S6K was also highly phosphorylated 
throughout mitosis and because the phosphorylation of S6K on the residue 421 and 424 is sensitive to mTOR 
inhibition, it is likely that the Akt/mTOR/S6K pathway plays a role TECs proliferation. 
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Inhibition of cystogenesis is a class effect of mTOR inhibitors 
Sirolimus slows polycystic kidney disease progression and to determine whether this is a class effect of all 
mTOR inhibitors we analyzed the effect of everolimus on cyst growth and renal function in Cy/+ [3]. 
Furthermore by applying 3 mg/kg/day everolimus by gavage feeding, we aimed to reach whole blood everolimus 
through levels between 5- 10 ng/ml, a drug level known to prevent organ rejection in rat models of renal 
allograft transplantation. Comparable to rapamycin, everolimus treatment for 5 weeks significantly inhibited cyst 
growth and 2-kidney weights in Cy/+ rats (Figure 1). Everolimus trough levels between 5 and 7 µg/l slowed 
renal functional deterioration and reduced the proliferation of TECs in Cy/+ rats. In summary, an everolimus 
dosage, clinically applied to prevent organ rejection, effectively inhibits cyst growth and the inhibitory effect of 
everolimus on cytogenesis most likely represents a class effect of mTOR inhibitors.  
 
Figure 1: Representative paraffin-embedded kidney sections of Han:SPRD rats showing the effect of everolimus 
treatment on kidney seize and cyst number  
 
(A) Wild type (+/+) kidneys after treatment with vehicle, (B) heterozygous (Cy/+) with vehicle and (C) 
heterozygous (Cy/+) with everolimus treatment showing a marked reduction of kidney size and reduced number 
of cysts.  
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Clinical research 
In human ADPKD progressive cyst growth generally precedes the development or renal insufficiency. 
Compensatory mechanisms (hyperfiltration) maintain renal function virtually normal for decades despite 
continuous cyst growth. By the time renal function starts to decline, the kidneys are usually grossly enlarged 
with little normal renal parenchyma recognisable on imaging studies. Data from the consortium for radiologic 
imaging studies of polycystic kidney disease (CRISP) and others have shown that the rate of kidney volume 
growth is a predictor of renal functional decline and therefore kidney volume is used as surrogate marker of 
disease progression especially in clinical intervention trials for ADPKD. Typically patients develop end-stage 
renal disease (ESRD) by the age of 40 to 50 years, necessitating renal replacement therapy (RRT) and/or kidney 
transplantation. Apart from blood pressure control and symptomatic treatment of cyst bleedings and infections 
there is no curative therapy for this disease.  
The SUISSE ADPKD [NCT00346918] study seeks to determine if sirolimus halts kidney volume growth in 
patients with ADPKD early in the disease course [5]. Study participation is restricted to young patients with 
preserved kidney function because we hypothesize that any effective treatment of ADPKD needs to be started 
early in the course of the disease to have an impact on long term kidney function. The study is a single center 
randomised controlled open label trial. The clinical study was designed and implanted and shall be reported in 
accordance with Guidelines for Good Clinical Practice (GCP) and with the ethical principles laid down in the 
Declaration of Helsinki. During the study an external field monitor visits the study center regularly to check the 
completeness of the patient records, the accuracy of entries on the CRFs, the adherence to the protocol and to 
GCP and to ensure that the study drug is being stored, dispensed, and accounted according to specifications.  
The primary objective of the SUISSE ADPKD study is to assess the effectiveness of sirolimus to retard kidney 
volume growth and to prevent the loss of renal function. The secondary objectives are to follow renal function 
and blood pressure and to monitor for the occurrence of proteinuria. In addition, cardiovascular function as 
assessed by echocardiography, ambulatory blood pressure measurements and electrocardiogram will be 
monitored. Safety and tolerability of sirolimus treatment in ADPKD patients will also be assessed. Patients with 
ADPKD and kidney volume growth that can be documented within 6 months are randomized to treatment with 
sirolimus 2 mg/day for 18 months or standard treatment (Figure Appendix). The study will involve 100 ADPKD-
patients aged 18-40 years with a creatinine clearance >70 ml/min. Kidney volumes will be measured by MRI 
without contrast media at study month 0 and 6. Patients with documented volume progression are randomized at 
a 1:1 ratio to sirolimus or standard treatment. Adherence to the prescribed study drug will be assessed by using 
the Medication Event Monitoring V Track-Cap System (MEMS®, Aardex, Ltd., Zug, Switzerland) during the 
complete treatment period. Principal statistical analysis will be undertaken using an intention-to-treat approach. 
A secondary on-treatment analysis will also be performed. The annual percent change in kidney volume will be 
determined by regressing the log transformed total kidney volume at month 6, 12 and month 24 against time for 
each patient through the least squares method. To account for possible baseline imbalances, a secondary analysis 
will be performed in which comparison of treatment groups for all endpoints will be adjusted for predefined 
covariates using multiple regressions (ANCOVA).  
Recruitment has started in May 2006 and finished December 2007. The study will be completed by December 
2009. Our trial is the first clinical study addressing this question. If sirolimus treatment can reduce or stop 
volume growth in patients with maintained kidney function and prior documented kidney volume progression, 
these ADPKD patients could benefit the most from a treatment with an anti-proliferative agent like sirolimus. 
Further information is available here: www.ADPKD.ch. Similar studies using specific mTOR inhibitors to halt 
disease progression have been announced by others (Mayo Clinic, USA; Certican® trial, Novartis, Germany). 
We anticipate that sirolimus might be an effective therapeutic option for ADPKD patients that are prone to 
progress to end-stage renal disease.  
 
Outlook 
To obtain a full understanding of the therapeutic potential of mTOR inhibitors in ADPKD and to optimally 
develop human therapies it is important to precisely unravel the mechanisms of action of these drugs, both in 
vitro and in vivo. Our ongoing basic research project supported by the SNF has the goal to characterize the 
mechanisms of the antiproliferative effect of rapamycin and everolimus on TECs in vitro and in vivo. The two 
mTOR inhibitors rapamycin and everolimus may not only display antiproliferative effects on renal cystic 
epithelia, but they have additional effects on matrix synthesis and degradation and on angiogenesis. Neo-
angiogenesis around cysts is a crucial process in PKD, and mTOR inhibitors might act in a beneficial way by a 
combined effect on tubular epithelial cell (TEC) proliferation, pericystic matrix turnover and angiogenesis. The 
results of these studies will provide a broader understanding of the mechanisms of action and the therapeutic 
potential of mTOR inhibitors to treat human ADPKD. We anticipate that mTOR inhibitors might be very 
effective drugs, due to their unique mechanism of action that targets cystic epithelia, matrix production and 
pericystic capillaries. Together with our proof-of-concept clinical trial that is currently recruiting patients we 
should be able to definitively prove the therapeutic potential of mTOR inhibitors for patients with ADPKD. 
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Inhibition of mTOR with sirolimus slows disease progression
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Abstract
Background. Autosomal dominant polycystic kidney
disease (ADPKD) is characterized by dysregulated
tubular epithelial cell growth, resulting in the forma-
tion of multiple renal cysts and progressive renal
failure. To date, there is no effective treatment for
ADPKD. The mammalian target of rapamycin
(mTOR) is an atypical protein kinase and a central
controller of cell growth and proliferation. We
examined the effect of the mTOR inhibitor sirolimus
(rapamycin) on renal functional loss and cyst progres-
sion in the Han:SPRD rat model of ADPKD.
Methods. Five-week-old male heterozygous cystic
(Cy/þ) and wild-type normal (þ/þ) rats were adminis-
tered sirolimus (2mg/kg/day) orally through the
drinking water for 3 months. The renal function was
monitored throughout the treatment phase, and rats
were sacriﬁced thereafter. Kidneys were analysed
histomorphometrically, and for the expression and
phosphorylation of S6K, a well-characterized target of
mTOR in the regulation of cell growth.
Results. The steady increase in BUN and creatinine
in Cy/þ rats was reduced by 39 and 34%, respectively
with sirolimus after 3 months treatment. Kidney
weight and 2-kidney/total body weight (2K/TBW)
ratios were reduced by 34 and 26% in sirolimus-treated
Cy/þ rats. Cyst volume density was also reduced by
18%. Of importance, Cy/þ rats displayed enhanced
levels of total and phosphorylated S6K. Sirolimus
effectively reduced total and phosphorylated levels
of S6K.
Conclusion. We conclude that oral sirolimus markedly
delays the loss of renal function and retards cyst
development in Han:SPRD rats with ADPKD.
Our data also suggest that activation of the S6K
signalling pathway plays an important role in the
pathogenesis of PKD. Sirolimus could be a useful drug
to retard progressive renal failure in patients with
ADPKD.
Keywords: ADPKD; Han:SPRD rats; mTOR;
rapamycin; sirolimus; S6K
Introduction
Autosomal-dominant polycystic kidney disease
(ADPKD) is the most common form of renal cystic
disease, affecting all ethnic groups worldwide, with an
incidence of 1 in 500 to 1 in 1000. The disease accounts
for up to 10% of all patients requiring renal replace-
ment therapy. Affected individuals usually present
in the 3rd and 4th decade of life, progressing to end-
stage renal disease (ESRD) within 5–10 years after the
development of renal insufﬁciency [1].
The disease is characterized by the progressive
development of ﬂuid-ﬁlled cysts in the kidney. The
renal cysts originate from the epithelia of the nephrons
and are lined by a single layer of cells that have a
higher rate of cellular growth and proliferation.
Various abnormalities in gene expression, ﬂuid secre-
tion, apoptosis and extracellular matrix production
have been described in ADPKD [2]. PKD1 and PKD2
encode for the proteins polycystin-1 and polycystin-2,
and various mutations in these genes are linked to the
occurrence of ADPKD [3–6]. How defects in these
genes lead to the massive cyst growth in patients with
ADPKD is being investigated [7].
Currently, there is no speciﬁc treatment for PKD
other than supportive care and blood pressure control.
Usually dialytic treatment or renal transplantation
Correspondence and offprint requests to: Prof. Dr Rudolf P.
Wu¨thrich, Renal Division, University Hospital, Ra¨mistrasse 100,
8091 Zu¨rich, Switzerland. Email: rudolf.wuethrich@usz.ch
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becomes necessary when the disease has progressed
to end-stage renal failure. There is signiﬁcant interest
in searching for speciﬁc drugs which decrease or halt
the progression of cyst development, thus slowing renal
functional deterioration and preventing the develop-
ment of ESRD [8–10].
The Han:SPRD rat is a well-known model of
ADPKD, although the gene defect has not been
identiﬁed yet [11]. Recently, the drug rapamycin
(sirolimus) – an inhibitor of the mammalian target of
rapamycin (mTOR) – was found to signiﬁcantly inhibit
cyst growth in the Han:SPRD rat [12]. The protein
kinase mTOR has emerged as a major effector of cell
growth and proliferation via the regulation of protein
synthesis. mTOR controls protein synthesis through
a number of downstream targets, some of which are
phosphorylated directly by mTOR, while others are
phosphorylated indirectly, and could be dysregulated
in ADPKD.
The mTOR inhibitor sirolimus is an immunosup-
pressant drug with antiproliferative and growth
inhibiting effects [13,14]. It is used clinically in
recipients of renal allografts to prevent transplant
rejection. It is also used in coated stents to prevent
coronary artery re-stenosis after angioplasty [15]. Very
recently, sirolimus has shown clinical effectiveness in
kidney transplant recipients with Kaposi’s sarcoma
[16]. We hypothesized that mTOR and its downstream
cell growth regulatory proteins are dysregulated in
PKD, and that sirolimus could be an effective oral drug
to inhibit cyst progression. We therefore used the
Han:SPRD rat model of ADPKD [11] to test the effect
of oral sirolimus (Rapamune) on loss of renal function
and cyst progression. We also examined the activity
of the mTOR downstream target S6K (p70S6K) [17] in
these ADPKD rats and tested the effect of sirolimus on
this effector protein.
Subjects and methods
Animals
The study was conducted in heterozygous (Cy/þ) and nor-
mal littermate control (þ/þ) Han:SPRD rats. Only male rats
were used since the disease progresses faster in male compared
with female rats. A colony of Han:SPRD rats was established
in our animal care facility from breeding pairs that were
obtained from the Rat Resource & Research Center
(Columbia, MO, USA). The study protocol was approved
by the regulatory commission for animal studies, a local
government agency. Rats had free access to tap water and
standard rat diet.
Study drug
Rapamune oral solution (1mg/ml) was kindly provided by
Wyeth-AHP (Schweiz) AG, Switzerland.
Experimental protocol
Male Cy/þ and þ/þ rats were weaned and were then treated
at 5 weeks of age (n¼ 12) with 2mg/kg/day sirolimus.
Additional male Cy/þ andþ/þ rats (n¼ 16) were not treated,
and they served as controls. The drug was administered in the
form of Rapamune oral solution (Wyeth) in the drinking
water for 3 months. Drinking bottles were protected from
light with aluminum foil and were changed every 2 days.
The concentration of sirolimus (Rapamune oral stock
solution 1mg/ml) was adjusted according to rat body
weight. Blood was drawn from the tail veins every month.
After 3 months treatment, rats were anaesthetized with
isoﬂurane, and kidneys were removed, decapsulated and
weighed. Slices of each kidney were preserved in 4%
paraformaldehyde and embedded in parafﬁn for histological
examinations. Additional slices were snap frozen in liquid
nitrogen and used for protein extraction.
Blood chemistry
Blood was collected in lithium-heparin tubes and centrifuged
at 4C. Plasma was stored at 20C, and was analysed later
for blood urea nitrogen (BUN) and creatinine using kinetic
color test and the modiﬁed Jaffe´ method, respectively. Blood
for sirolimus levels was collected under the same conditions,
but using EDTA tubes and analysed using HPLC-mass
spectroscopy. All samples were analysed at the Institute
for Clinical Chemistry, University Hospital (Zu¨rich,
Switzerland).
Histology
Mid-transversal slices of the kidney, about 2mm-thick, were
ﬁxed by immersion in phosphate-buffered 4% paraformalde-
hyde, dehydrated in alcohol series and embedded in parafﬁn.
Three micrometer thick sections were stained with the
periodic acid-Schiff (PAS) technique. The cyst volume density
(CVD) was evaluated in these sections by morphometry,
using the technique of point counting [18].
To avoid subjective sampling biases, micrographs for
morphometry were taken according to an invariable protocol.
At the magniﬁcation used (Zeiss Plan-Neoﬂuar 10/0.30), the
diameter of the ﬁeld of view was close to the thickness of the
renal cortex in healthy rats. The ﬁrst micrograph was taken as
the ﬁeld was positioned on one extremity of the horseshoe-
shaped cortex. For further sampling, the microscope stage
was moved clockwise by steps of one ﬁeld diameter, while
the surface of the kidney remained at the limit of the ﬁeld.
A micrograph was made at every second step. A total of 4–6
micrographs was obtained for one section. One section was
evaluated per rat. The pixel size of the micrographs was
1300 1030 (1.34 mm/pixel). The cyst volume density of cysts
was evaluated by point counting. An orthogonal grid with
a line spacing of 150 pixels was used. The person responsible
for morphologic documentation and for morphometry was
blinded to the experimental groups.
Analysis of S6K activity
The amount of total and phosphorylated S6K was assessed
by immunoblotting, using speciﬁc antibodies. Samples of
kidney tissue were snap-frozen in liquid nitrogen and stored at
80C. On the day of immunoblotting, ice-cold lysis buffer
was prepared. The lysis buffer consisted of 50mM Tris base,
pH 7.4; 150mM NaCl; 1% deoxycholate; 1% SDS; and 1%
Triton X-100. Immediately before use, the lysis buffer was
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supplemented with 1mM PMSF, 10 mg/ml aprotinin,
10mg/ml leupeptin, and protease and phosphatase inhibitor
cocktail. Each sample was homogenized in this buffer with
a Dounce homogenizer. The protein concentration of each
sample was measured.
SDS-PAGE sample buffer was added to the extracts.
Extracts were heated to 90C for 5min for denaturation.
A total of 30 mg protein was loaded per lane for standard
SDS-PAGE (7.5%), and Western analysis. The following
antibodies were used for detection: sc-230 (St Cruz
Biotechnology, Inc., Santa Cruz, CA, USA; detects S6K),
#9205 and #9204 (Cell Signaling Technology, Inc., Beverly,
MA, USA; detect S6K phosphorylated on Thr389 and
Thr 421/Ser424, respectively), and MAB 1501 (Chemicon,
Temecula, CA, USA; detects actin). For signal detection,
horseradish peroxidase-conjugated secondary antibodies
and SuperSignal Femto/Pico ECL kits were used (Pierce
Biotechnology, Rockford, IL, USA).
Statistical analysis
Data are presented as means±SD and were analysed by
one-way ANOVA with post-test according to Newman–
Keuls. A P-value of <0.05 was considered signiﬁcant.
Results
Judging by physical appearance, the treatment with
sirolimus was well tolerated. None of the 12 sirolimus-
treated rats died, and all 16 control rats survived.
Sirolimus blood levels were obtained in all treated
animals, and were between 0.5 and 1.9 mg/l. Figure 1
shows that body weight increased steadily in untreated
and sirolimus treated Cy/þ and þ/þ rats. Treatment
with sirolimus did not signiﬁcantly change body weight
after 3 months of treatment (3.3% in þ/þ and 11%
in Cy/þ rats).
Renal functional loss is inhibited with sirolimus
Figure 2 demonstrates that the BUN and creatinine
levels remained within normal limits in þ/þ rats but
increased progressively in untreated Cy/þ rats. BUN
and creatinine levels also increased in sirolimus-treated
Cy/þ rats, but to a lesser degree. After 3 months of
treatment, the average BUN level was 39% less in
sirolimus-treated Cy/þ rats (n¼ 7) compared with
untreated Cy/þ rats (n¼ 9) (45.6±4.2 vs 75.3±
16.9mg/dl; P<0.001), and creatinine levels were 34%
less (0.89±0.13 vs 1.34±0.24mg/dl; P<0.001). This
demonstrates that sirolimus effectively inhibited the
loss of renal function in male Han:SPRD rats.
Renal weight and cyst volume density
are reduced with sirolimus
Figure 3 shows that the increase in kidney weight was
effectively reduced in sirolimus-treated Cy/þ compared
with untreated Cy/þ rats. Treatment with sirolimus
resulted in a 34% lower kidney weight in Cy/þ rats.
Sirolimus treatment did not have a signiﬁcant effect
on kidney weight in wild-type þ/þ rats (Figure 3A).
We also determined the 2K/TBW ratios. Figure 3B
demonstrates that sirolimus reduced the 2K/TBW ratio
by 26% in Cy/þ rats.
Histological examination of the Han:SPRD kidneys
revealed a signiﬁcant reduction in cyst size in sirolimus-
treated Cy/þ rats compared with untreated Cy/þ
animals (Figure 4). A more detailed microscopical
examination revealed the presence of tubular cysts in
the cortex, and to a lesser extent in the outer medulla
of untreated Cy/þ kidneys. The inner medulla was
not affected. Cystic expansion of Bowman’s capsule
was observed in a few glomeruli. Mononuclear cell
inﬁltrates were observed focally in the peritubular
interstitium. This histopathological pattern was not
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Fig. 1. Weight gain (g) in the four animal groups at 1, 2, 3 and 4 months of age. Treatment with sirolimus was started at 5 weeks and did
not signiﬁcantly inﬂuence weight gain (ANOVA).
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affected qualitatively by sirolimus treatment in Cy/þ
kidneys. Untreated and sirolimus-treated wild-type
þ/þ kidneys showed no difference in histology (data
not shown).
The most signiﬁcant effect of sirolimus on kidney
histology was a signiﬁcant reduction of the cyst volume
density in the cortex of Cy/þ rats. Figure 5 demon-
strates that cyst volume density was 18% less in
sirolimus-treated Cyþ/rats (P<0.001). Since the refer-
ence volume for evaluation of volume density was the
total cortical volume and since sirolimus treatment
considerably reduced the increase of kidney weight
in Cy/þ rats, the effect of sirolimus on the cyst volume
density certainly underestimates its effect on the
absolute volume of cysts.
Total and phosphorylated levels of S6K
are enhanced in ADPKD rats
mTOR controls protein synthesis and cell growth by
phosphorylating and thereby activating the 70 kDa
ribosomal S6 kinase (S6K) [19]. Thus far it has not
been tested whether mTOR-S6K signalling is altered in
ADPKD, and whether the mTOR inhibitor sirolimus
affects ADPKD. We therefore examined S6K expres-
sion and phosphorylation in untreated and sirolimus-
treated Cy/þ rats. Figure 6 shows that total levels of
S6K are markedly increased in the kidneys of 4-month-
old Cy/þ Han:SPRD rats compared with wild-
type þ/þ rats. The level of expression of S6K was
effectively reduced in sirolimus-treated Cy/þ rats.
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Fig. 2. Blood urea nitrogen (BUN) (A) and serum creatinine (B) levels were measured monthly in all rats. The rise in BUN and creatinine
was signiﬁcantly reduced by sirolimus in Cy/þ rats.
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We then measured the activity of S6K by analysing
the mTOR-dependent phosphorylation of S6K at
threonine 389 and threonine 421/serine 424 [20–23].
Figure 5 shows that the phosphorylated forms of S6K
were undetectable in normal þ/þ kidneys, but mark-
edly enhanced in Cy/þ kidneys. Sirolimus effectively
reduced phosphorylation at Thr389 and Thr421/Ser424
of S6K in Cy/þ kidneys. Overall, there was an excellent
correlation between the histomorphometric ﬁndings
and the degree of S6K phosphorylation.
Discussion
The massive and spontaneous development of cysts
results in progressive deterioration of renal function
in male Han:SPRD rats. This leads to symptomatic
renal failure and premature death in these animals.
Here, we demonstrate that sirolimus, when given orally
for 3 months, signiﬁcantly improves renal function in
male Han:SPRD rats. Sirolimus treatment effectively
Fig. 4. Parafﬁn sections of kidneys of a wild-type, sirolimus-treated
(A), of a Cy/þ untreated (B) and of a Cy/þ sirolimus-treated rat
(C). Sirolimus reduced the kidney size, cyst volume and cyst density
markedly in Cy/þ rats. PAS staining. Bar length: 1.5mm.
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Fig. 3. The 2-kidney weights (2KWt) (A) and 2-kidney/total body
weight (2K/TBWt) ratios (B) were determined after 3 months of
treatment with sirolimus. Both parameters were signiﬁcantly
reduced by sirolimus in Cy/þ rats. *P<0.001 (Cy/þ untreated vs
þ/þ untreated); **P<0.001 (Cy/þ untreated vs Cy/þ sirolimus-
treated).
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Fig. 5. Cyst volume density (CVD) was massive in Cy/þ rats and
was signiﬁcantly decreased (18%) in sirolimus-treated Cy/þ rats.
*P<0.001 (Cy/þ untreated vs Cy/þ sirolimus-treated).
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controlled the massive increase in kidney weight in
Cy/þ rats and signiﬁcantly reduced the cyst volume
density. Our data conﬁrm and extend a very recent
report by Tao et al. [12]. They found that rapamycin,
when injected intraperitoneally for 5 weeks, improved
renal function and slowed cyst progression in the same
rat model of ADPKD.
We applied sirolimus by using the Rapamune oral
solution. This is the galenic form which is approved
to prevent graft rejection in renal transplant patients.
Using a 2mg/kg/day dose resulted in relatively low
blood levels in our animals (between 0.5 and 1.9 mg/l).
This indicates that the drug was absorbed poorly.
Despite these low levels, the therapeutic effect was
impressive. Tao et al. used a different preparation of
sirolimus at a 10-fold lower daily dose intraperitoneally
[12]. They did not measure blood levels, but judging
by the signiﬁcantly reduced body weight (22%) in
their rapamycin-treated rats it is likely that blood levels
were higher in their animals. The 3-month treatment
was well tolerated in our rats with no signiﬁcant effect
on body weight.
In the study by Tao et al., treatment with sirolimus
did not completely prevent progression of cystic disease
[12]. This was the case in our study also. However,
both studies show that the treatment with sirolimus
markedly retarded renal functional loss. In our study
we treated animals for an extended period of 3 months
and found a continued inhibitory effect on renal
functional loss and cystic expansion. More studies are
needed to determine whether mortality is reduced in
Han:SPRD rats by prolonging treatment with sirolimus
or other mTOR inhibitors.
Sirolimus is known to inhibit its molecular target
mTOR. As it was highly effective in Han:SPRD
rats, we hypothesize that the mTOR pathway is
dysregulated in the kidneys of these rats. mTOR
regulates a vast array of cellular functions, and
promotes cell growth and proliferation [19]. A well-
characterized function of mTOR in mammalian cells is
the upregulation of protein synthesis via S6K, a
direct substrate of mTOR. Phosphorylation of S6K
by mTOR enhances translation of certain mRNAs,
which play an important role in translation regulation,
increasing thereby the overall translation capacity of
cells [24].
We describe here for the ﬁrst time that total amounts
of S6K and activity of S6K (determined as phosphor-
ylation of S6K) are enhanced in the kidneys of
Han:SPRD rats with ADPKD and that this can be
reversed by the application of sirolimus. In an acute
renal failure model, it has been shown that activated
S6K is increased in rat kidneys, suggesting that this
signalling pathway is activated in other types of renal
injury [17]. The mechanisms which lead to the enhanced
expression and phosphorylation of S6K in cystic
kidneys of Han:SPRD need to be investigated further.
Our ﬁndings point to an important role of the mTOR
pathway in Han:SPRD. We hypothesize that there
could be an interaction between molecules which are
defective in Han:SPRD and the mTOR pathway in
the pathogenesis of cyst growth. The nature and the
importance of these interactions need to be investigated
in further studies.
In summary, we demonstrate that oral sirolimus
markedly inhibits the rapid deterioration of renal
function by inhibiting cyst growth in Han:SPRD rats
with ADPKD. We speculate that mTOR and its
downstream effector S6K play a critical role in the
pathogenesis of ADPKD. Further studies are in
progress to elucidate the mechanisms of the altered
expression and phosphorylation of these proteins,
and to examine the effect of mTOR inhibition in
other animal models of cystic kidney disease.
actin
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Fig. 6. SDS-PAGE and Western blot analysis from kidney protein extracts for total amounts of S6K, phosphorylated S6K (Thr389, and
Thr421/Ser424) and actin. Two representative animals were analyzed from each group. The amount of total and phosphorylated S6K was
markedly increased in Cy/þ kidneys (lanes 5 and 6), and this was effectively suppressed by sirolimus (lanes 7 and 8).
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Mitotic activation of Akt signalling pathway in Han:SPRD
rats with polycystic kidney disease
PATRICIA R WAHL,1 MICHEL LE HIR,2 ALEXANDER VOGETSEDER,2 ALEXANDRE ARCARO,3
ASTRID STARKE,1 YING WAECKERLE-MEN,1 ANDREAS L SERRA1,4 and
RUDOLF P WUTHRICH1,4
1Physiological Institute and Zurich Center for Human Integrative Human Physiology and 2Anatomical Institute,
University Zurich-Irchel, 3Division of Clinical Chemistry and Biochemistry, University Children’s Hospital, and
4Clinic for Nephrology, University Hospital, Zurich, Switzerland
SUMMARY:
Aim: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by an imbalance between
tubular epithelial cell proliferation and apoptosis. We have previously shown that the mammalian target of
rapamycin (mTOR) signalling pathway is aberrantly activated in the cystic kidneys of Han:SPRD rats with
ADPKD. Because the Akt kinase is an upstream regulator of mTOR, we hypothesized that the activity of Akt could
be enhanced in the kidneys of Han:SPRD rats.
Methods: Reverse transcription-polymerase chain reaction, western blot, enzyme-linked immunosorbent assay
and immunohistochemistry were used to analyse Akt expression in rat polycystic kidneys.
Results: Wild-type (+/+) and heterozygous (Cy/+) Han:SPRD rats showed constitutive expression of Akt-1, -2
and -3 mRNA by reverse transcription-polymerase chain reaction analysis with no significant difference between
Cy/+ and +/+ kidneys. Western blotting and enzyme-linked immunosorbent assay showed a significant increase
in phosphorylated Akt in Cy/+ compared with +/+ kidneys. The pattern of immunoreactivity for phosphorylated Akt
in kidney sections was the same in +/+ and in Cy/+ rats, with very low levels in interphase cells, but extremely
bright signals in mitotic cells, beginning with the onset of the prophase. The in vivo incorporation of bromo-
deoxyuridine revealed approximately a ninefold higher rate of proliferation in Cy/+ cyst epithelia compared with
normal tubule epithelia in +/+ rats, while the expression of the cell cycle marker Ki67 revealed approximately a
sixfold higher rate of proliferation. In summary, enhanced phosphorylation of Akt can be demonstrated in Cy/+
kidneys which correlates with a markedly elevated proliferation rate of epithelial cells in cysts. Mitotic but not
resting cells display strong phosphorylation of Akt.
Conclusion: Because Akt is a proximal target of mTOR, its inhibition with specific antagonists could be useful
to prevent or halt cystogenesis in ADPKD.
KEY WORDS: ADPKD, Akt kinase, cell proliferation, Han:SPRD rat, mitosis, mTOR.
Autosomal dominant polycystic kidney disease (ADPKD) is
a common monogenetic disorder affecting as many as 1 in
800 people in the general population.1,2 The disease is char-
acterized by the formation of multiple fluid-filled renal cysts
that expand over time and destroy the architecture of the
kidney. About 8–10% of all cases of chronic renal failure are
due to ADPKD, and around 50% of ADPKD patients will
develop end-stage renal disease by the time they are 60 years
of age.1,2
Renal cyst formation is due to enhanced proliferation of
tubular epithelial cells.3 Microdissection of cystic kidneys
has revealed that cystic enlargement is due to an increase in
the number of epithelial cells lining the cyst and not to the
stretching of the cyst epithelium.4,5 Additionally, cultured
epithelial cells from ADPKD cysts display an enhanced
proliferation rate, and genes associated with increased
proliferation are overexpressed in cystic epithelium.6
The mammalian target of rapamycin (mTOR), a serine/
threonine kinase, plays an important role in the transla-
tional control of gene expression during cell growth, and for
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the overall rate of protein synthesis in response to nutrients
and other environmental factors.7 The mTOR kinase is also
a key intermediary in multiple mitogenic signalling path-
ways. Thus, mTOR plays a central role in regulating cell
proliferation, such as angiogenesis in normal tissues, and
neoplastic cell growth. An important pathway by which
growth factors and cytokines activate mTOR and its down-
stream targets is represented by the phosphoinositide
3-kinase (PI3K)/Akt pathway.8
There is evidence that signals upstream from mTOR are
activated in ADPKD. The serine/threonine protein kinase
Akt, a downstream effector of PI3K, has emerged as a criti-
cal mediator of mTOR activity.8 The mTOR kinase pos-
sesses two adjacent phosphorylation sites (Thr 2446 and Ser
2448), and it is known that Ser 2448 is directly phosphory-
lated by Akt.9–11 Recently, it has been shown that Akt is
also linked to mTOR via tuberin (TSC2) which is directly
phosphorylated by Akt.12,13
We have previously shown that mTOR is involved in the
progression of cyst development in the Han:SPRD model of
ADPKD.14 The purpose of the present investigation was to
determine whether Akt kinase, an upstream regulator of
mTOR, is also activated in the kidney of Han:SPRD rats, a
well-characterized rodent model of ADPKD. Here we show
that phosphorylated Akt (p-Akt) is markedly increased in
heterozygous (Cy/+) Han:SPRD rats in comparison with
wild-type (+/+) rats, particularly in cells undergoing mitosis,
correlating with an increased proliferation of epithelial cells
in cysts.
METHODS
Reagents
Unless otherwise stated, all reagents used were from Sigma (St. Louis,
MO, USA).
Animals
The study was conducted in heterozygous (Cy/+) and normal littermate
control (+/+) Han:SPRD rats. Only male rats were used because the
disease progresses faster in male compared with female rats. A colony of
Han:SPRD rats was established in our animal care facility from breed-
ing pairs that were obtained from the Rat Resource & Research Center
(Columbia, MO, USA). The study protocol was approved by the regu-
latory commission for animal studies, a local government agency.
Unless otherwise stated, the rats had free access to tap water and
standard rat diet. For immunohistochemistry 8-week-old rats were
injected with 0.3 mL of bromo-deoxyuridine (BrdU) subcutaneously at
10 am on day 0 because this is the stage of cyst progression at which
proliferation is at its peak. From that time on, the drinking solution
consisted of 1 mg/mL BrdU – a synthetic analogue of thymidine – in tap
water up to sacrifice 4 days later between 9 am and 11 am. When
applied in vivo, BrdU is incorporated in the DNA of cycling cells,
allowing detection by specific antibodies. In addition, 16-week-old rats
were sacrificed and kidneys were removed for mRNA and protein
extraction. This later time point was chosen to detect more significant
changes in RNA and protein levels, because previous results using gene
array analyses (data not shown) have revealed that expression changes
were generally more apparent in older animals. After decapsulation,
kidney slices were prepared and were stored in RNAlater (Qiagen,
Basel, Switzerland), an RNA stabilization solution for tissue, or were
snap frozen in liquid nitrogen for protein extraction. All samples were
stored at -80°C.
RNA extraction and RT-PCR for Akt
Kidney tissue was mechanically disrupted with 0.1 mm diameter
zirconia-silica beads in a Fast Prep FP120 instrument (Qbiogene,
Heidelberg, Germany). RNA isolation from this lysate was performed
with a Qiagen RNeasy mini kit (Qiagen, Basel, Switzerland), according
to the instructions of the supplier. All RNA samples were quantified by
measurement of the OD at 260 nm and were then analysed for Akt
expression by semiquantitative reverse transcription-polymerase chain
reaction (RT-PCR), using a Qiagen OneStep PCR kit (Qiagen, Basel,
Switzerland). Varying numbers of cycles (25–35) were performed to
ensure that the PCR analysis was in the linear phase of amplification.
The primer sequences for rat Akt-1, -2 and -3 and the housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase were determined
by using Primer 3 software (http://www.genome.wi.mit.edu/cgi-bin/
primer/primer3_www.cgi). RT-PCR products were resolved on 1%
agarose gels, and were stained with ethidium bromide and then
photographed with ultraviolet light.
Protein extraction
To prepare protein extracts, frozen kidney tissue samples were homog-
enized, using a Dounce homogenizer in T-PER extraction reagent
(Pierce, Rockford, IL, USA). Immediately before use, the lysis buffer
was supplemented with 1 mM PMSF, Halt™ protease and Halt™ phos-
phatase inhibitor cocktail (Pierce, Rockford, IL, USA). After centrifu-
gation at 10 000 ¥ g for 5 min, supernatants were adjusted for protein
concentration, and were used for western blotting and enzyme-linked
immunosorbent assay (ELISA).
Western blot
Frozen cell lysates were defrosted and equal amounts of protein
(0.335 mg) diluted to 0.5 mL using lysis buffer (20 mM HEPES
(pH 7.4), 150 mM NaCl, 10% (w/v) glycerol, 1% (w/v) Triton X-100,
2 mM EDTA, 10 mM sodium fluoride, 1 mM phenylmethylsul-
phonyl fluoride, 5 mM benzamidine, 1 mM Na-tosyl-L-lysine
chloromethyl ketone, 20 mM leupeptin, 18 mM pepstatin, 10 mM
b-glycerophosphate, 2 mM sodium orthovanadate). Immunoprecipita-
tion was performed using polyclonal rabbit anti-Akt1/2 antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) and protein
A-sepharose CL-4B (GE Healthcare Bio-Sciences Corp., Piscataway,
NJ, USA). Samples were incubated for 3 h at 4°C with constant
mixing. The immunoprecipitates were then washed three times with
1 mL of lysis buffer and boiled in SDS-PAGE sample buffer. The
samples were analysed by SDS-PAGE (10%, reducing) and western
blotting, using polyclonal rabbit antiphospho-Akt antibody (Ser473,
Cell Signalling Technology, Danvers, MA, USA). Blots were devel-
oped using enhanced chemiluminescence (ECL kit, GE Healthcare
Bio-Sciences Corp., Piscataway, NJ, USA).
ELISA
Expression levels of total and p-Akt (phosphorylation sites Ser473 and
Thr308) were determined by sensitive and specific ELISA (Sigma, St.
Louis, MO, USA). A monoclonal capture antibody specific for Akt
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(independent of phosphorylation) was coated onto a 96-well plate.
Standard dilutions and equal concentrations of samples were incubated
for 2 h at RT allowing Akt antigen to bind to the capture antibody.
After washing, a detection antibody specific for either total Akt, p-Akt
(Ser473), or p-Akt (Thr308) was added and incubated for 1 h at RT.
After washing, an anti-rabbit IgG-HRP was added. The reaction was
visualized by tetramethylbenzidine (TMB) substrate, followed by the
addition of stop solution. The optical density was measured in a multi-
well plate reader at 450 nm and is directly proportional to the concen-
tration of Akt/PKB in the sample. The values of p-Akt (Ser473) and
p-Akt (Thr308) were normalized for total Akt content.
Immunohistochemistry
Fixation and tissue treatment
The rats were anaesthetized by an intraperitoneal injection of pento-
barbital (100 mg/kg body weight) and fixed by vascular perfusion.15 The
fixative contained 3% paraformaldehyde, 0.01% glutardialdehyde and
0.5% picric acid, dissolved in a 3:2 mixture of 0.1 M cacodylate buffer
(pH 7.4, added with sucrose, final osmolality 300 mosmol) and 4%
hydroxyl ethyl starch (Fresenius Kabi, Bad Homburg, Germany) in
0.9% NaCl. The kidneys were fixed for 5 min, and then rinsed by
vascular perfusion with 0.1 M cacodylate buffer for 5 min.
Immunofluorescence staining
2 mm slices of fixed kidney were frozen in liquid propane which was
cooled down to the temperature of liquid nitrogen, and were cut into
4 mm cryostat sections. Sections were thawed on slides and microwaved
for 10 min in 0.01 M citrate buffer at pH 6.0. After pretreatment for 1 h
in 5% normal goat serum in phosphate-buffered saline, the sections
were incubated overnight in a humidified chamber at 4°C with the
primary antibodies, diluted in phosphate-buffered saline supplemented
with 1% bovine serum albumin. p-Akt (rabbit anti-p-Akt (Thr308)),
p-S6 kinase (rabbit anti-p-S6K(Thr421/Ser424)) (both Cell Signalling
Technology, Danvers, MA, USA), BrdU (mouse anti-BrdU clone B44,
BD Biosciences Pharmingen, San Diego, CA, USA) and the prolifera-
tion marker Ki67 (rabbit anti-Ki67, Novocastra Laboratories Ltd.,
Newcastle, UK) were analysed on cryostat sections. Binding sites of the
primary antibodies were revealed with Cy3-conjugated goat-anti-rabbit
IgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA).
For nuclear staining, 4′,6-diamidino-2-phenylindole (DAPI; Sigma, St.
Louis, MO, USA) was added to the working dilution of the secondary
antibodies.
Quantitative evaluation of nuclear labelling
Using the nuclear DNA-labelling of DAPI, the outer stripe and cortex
were located and micrographs were made randomly, using the 40¥
magnification of a laser scanning microscope (CLSM SP2, Leica, Man-
nheim, Germany). The surface area of tissue evaluated for each rat was
3.5 mm2. The proximal tubule was identified by the brush border,
detectable in background fluorescence. Nuclei of proximal epithelial
cells positive for BrdU, and/or Ki67 were counted in all proximal
tubules in the micrographs. DAPI fluorescence was used for assessment
of the total number of nuclei in the proximal tubules. Because of the
high number of DAPI-positive cells, these were evaluated in a uniform
random systematic sample (10% sampling fraction) of the area of the
micrograph. Those parameters were evaluated separately in cystic
tubules and normal tubules.
Statistical analysis
Unless otherwise stated, data are presented as means 1 SEM and were
analysed by Student’s t-test for unpaired samples. A P-value of <0.05
was considered significant. Statistical analysis of the data was performed
with the GraphPad Prism software (GraphPad Software Inc. San Diego,
CA, USA).
RESULTS
Renal Akt mRNA expression in Cy/+ and +/+ rats
First, we examined the kidneys of Cy/+ and wild-type +/+
rats for the presence of the three different Akt mRNAs,
using specific primers for Akt-1, -2 and -3 and RT-PCR
analysis. Figure 1 shows that all three Akt mRNA tran-
scripts were constitutively expressed. This RT-PCR analysis
did not reveal a distinct difference between healthy +/+
kidneys and polycystic Cy/+ kidneys.
Upregulation of p-Akt in Cy/+ versus +/+ rats
We then examined whether an enhanced activity of Akt
could be found in Cy/+ kidneys, as revealed by phosphory-
lation of Akt at Ser473. Total Akt was immunoprecipitated
from protein extracts of Cy/+ and +/+ kidneys, was separated
by SDS-PAGE and analysed by western blot using an
Fig. 1 Reverse transcription-polymerase chain reaction
mRNA expression of the three Akt isoforms in 16-week-old
wild-type (+/+) and heterozygous (Cy/+) rats. Akt-1, -2 and -3
mRNA transcript levels are all constitutively expressed,
with no change between the two strains. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as a house-
keeping gene to ensure equal amounts of mRNA. Results are
representative of repeated experiments.
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antibody which targets the Ser473 phosphorylation site.
Figure 2 shows that p-Akt (Ser473) was only weakly detect-
able in healthy 16-week-old rats. However, there was a
significant increase in the expression levels in age-matched
heterozygous (Cy/+) rats.
We confirmed the increase in Akt activity, using sensi-
tive and specific ELISA for p-Akt, examining both the
Ser473 and the Thr308 phosphorylation sites. Figure 3A
shows that there was a significant increase in the activity
level of p-Akt at Ser473 in heterozygous (Cy/+) kidneys, as
compared with untreated wild-type (+/+) kidneys (2.5-fold
increase; P 2 0.001). Figure 3B shows that there was also a
significant increase in levels of p-Akt at Thr308 in heterozy-
gous (Cy/+) versus untreated wild-type (+/+) rats (1.3-fold
increase; P 2 0.05). Thus, Akt phosphorylation is enhanced
at both sites in Cy/+ kidneys.
High levels of p-Akt and p-S6K in mitotic cells
We then examined the expression of p-Akt at Thr308 in
kidneys of Cy/+ and +/+ rats by immunofluorescence stain-
ing. Figure 4 shows that p-Akt was detected only in a small
fraction of tubular cells. Examination of the chromatin in
the blue channel (DAPI) revealed that all of those cells
were undergoing mitosis. Immunolabelling for p-Akt was
weak to moderate in the prophase and it was restricted to
the nucleus. In the metaphase and the anaphase, the fluo-
rescence was very bright and it decreased sharply in the
telophase. A very similar pattern was observed for p-S6K, a
downstream effector in the Akt pathway, with a weak signal
in the interphase, a moderate-to-strong nuclear fluorescence
in the prophase and very bright fluorescence in the meta-
phase and the anaphase. Figure 5 shows a typical cyst with a
cell in metaphase that is brightly positive for p-S6K.
Increased cell proliferation in cysts of Cy/+
Han:SPRD rats
In Figure 6, it can be seen that the increased proliferation
rate in the Cy/+ rat is completely attributable to cyst epi-
thelia, because in normal tubules of Cy/+ rats the incidence
of cells labelled with BrdU or Ki67 were not significantly
different from values in +/+ rats. At 8 weeks of age the
percentage of BrdU-positive tubular cells in the cortex was
4.0% in +/+ rats, 5.3% in Cy/+ rats and reached 37.5% in
cyst epithelia. The corresponding numbers for Ki67 were
1.2%, 1.0% and 7.3%.
DISCUSSION
Here we show that the phosphorylation of Akt kinase and
hence its activity is markedly elevated in the kidney of
Han:SPRD rats with polycystic kidney disease. It has been
shown that Akt is activated by phospholipid binding and
activation loop phosphorylation at Thr308 and by phospho-
rylation within the carboxy terminus at Ser473. Phospho-
rylation of both sites is necessary for full activation.16
Enhanced phosphorylation of Akt was evident at Ser473
and Thr308 in heterozygous Cy/+ compared with wild-type
+/+ kidneys. The most striking observation was p-Akt in
Fig. 2 SDS-PAGE and western blot analysis of protein extracts
from 16-week-old male Cy/+ and +/+ rat kidney tissue samples,
testing for phosphorylated Akt (p-Akt) (Ser473). The amount
of p-Akt was markedly increased in Cy/+ rat kidneys. Results
are representative of several repeated experiments.
Fig. 3 Protein samples from 16-week-old wild-type (+/+) and
heterozygous (Cy/+) male rats were analysed for (A) phospho-
rylated Akt (p-Akt) (Ser473) or (B) p-Akt (Thr308), using
sensitive enzyme-linked immunosorbent assay. There was a
significant increase in both phosphorylated forms of Akt in
heterozygous Cy/+ in comparison to wild-type (+/+) rats.
*P 2 0.05, **P 2 0.001.
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mitotic cells, starting with the prophase. This suggests that
activation of Akt is instrumental in mitosis in tubular
epithelial cells. Because an enhanced proliferation rate of
epithelial cells is central in cyst formation, Akt could be an
attractive target for treating ADPKD.
The detection of p-Akt in mitotic cells fits with previous
studies showing the requirement for Akt activation in G2/M
transition in cell culture.6,17 Because we observed previously
that phosphorylation of S6K, a downstream member of the
Akt signalling cascade, is increased in ADPKD rats, we were
interested in examining the distribution of p-S6K(Thr421/
Ser424) by immunofluorescence. Like Akt, S6K was highly
phosphorylated throughout mitosis. Because the phospho-
rylation of S6K on the residues 421 and 424 is sensitive to
mTOR inhibition,18,19 it is likely that the Akt/mTOR/S6K
pathway plays a role in mitosis in tubular epithelial cells.
Others and we have recently shown that mTOR and its
downstream target S6K are markedly activated in polycystic
kidney disease. Thus, we could show that S6K, a key regu-
lator of cell growth and proliferation is aberrantly phospho-
rylated in the Han:SPRD rat, a model of ADPKD.14 Tao
et al. as well as our group could also show that rapamycin
treatment of Han:SPRD rats markedly delayed cyst growth
and renal functional deterioration in these animals.14,20 Shil-
lingford et al. extended these findings to three mouse models
of cystic diseases with different affected genes, as well as in
human renal tissue samples from patients with ADPKD.21 In
their landmark paper, they also provided evidence that
tuberin (TSC2), a protein that directly inhibits mTOR,
associated with polycystin 1, is the gene which is defective
in 85% of patients with ADPKD.21 They suggested that
mutations in polycystin 1 could lead to aberrant activation
of mTOR, thus allowing phosphorylation of S6K, the
master switch of cell growth and proliferation.
The activity of the mTOR kinase may not be solely
regulated by tuberin. Renal cyst fluid from PKD mice and
rodent models contain epidermal growth factor (EGF)-like
peptides in mitogenic concentrations.22–24 EGF has also been
shown to induce proximal tubular cyst formation in murine
metanephric organ cultures.25 It is well established in
various systems that EGF receptor (EGFR) ligation leads to
activation of phosphatidylinositol 3-kinase (PI3K). Akt
activation is one of the major downstream events of PI3K
signalling. Navé et al. showed that Akt, as part of the PI3K/
Fig. 4 Localization of phosphorylated Akt (p-Akt) (Thr308)
by immunofluorescence. A normal proximal tubule (A, B) and
a cyst (C) are shown in the kidney of a 2-month-old male Cy/+
rat. (A) p-Akt positivity in a nucleus of a cell in prophase
(arrowhead). The prophase nucleus, but not the neighbouring
interphase nuclei, is positive for p-Akt. (B) the pattern of DAPI
fluorescence indicates that the cell shown in A is in the
prophase (arrowhead). (C) Dual staining for p-Akt and DAPI.
A cell in the metaphase in a cyst is positive for p-Akt (red). The
insert shows the blue channel alone (chromatin staining with
DAPI), demonstrating mitosis in the p-Akt-positive cell. The
green channel displays background fluorescence of the tissue.
Bar: 10 mm in A and B, 100 mm in C.
Fig. 5 Localization of phosphorylated S6K (p-S6K) (Thr421/
Ser424) by immunofluorescence. A cell in the metaphase in a
cyst is strongly positive for p-S6K (red), whereas interphase
nuclei show only a faint signal. The insert shows the blue
channel alone (chromatin staining with DAPI), demonstrating
mitosis in the p-S6K-positive cell. The green channel displays
background fluorescence of the tissue. Bar: 100 mm.
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Akt pathway, directly targets mTOR, modulating the sig-
nalling pathways involved in protein translation.10 Thus, it
might be possible that the PI3K/Akt kinase pathway acti-
vates mTOR in a major way because of the enhanced EGFR
activation which is characteristic in ADPKD. In support of
this hypothesis is an experimental study with an EGFR
tyrosine kinase inhibitor which attenuated the development
of PKD in Han:SPRD rats.26
In summary, we provide evidence that activation of Akt
via phosphorylation at Ser473 and Thr308 occurs in the
early phase of polycystic kidney disease in the Han:SPRD
model of ADPKD. We hypothesize that mTOR activation
by the PI3K/Akt pathway occurs in addition to the
polycystin-1-dependent regulation of mTOR via tuberin.
Although we do not know precisely which signals activate
Akt in ADPKD, it is tempting to speculate that Akt inhi-
bition with selective antagonist could have a beneficial
therapeutic effect in ADPKD.
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 Introduction 
 Autosomal dominant polycystic kidney disease
(ADPKD) is one of the leading causes of end-stage kidney 
disease and occurs in 1–2 per 1,000 live births  [1, 2] . The 
disease is characterized by aberrant proliferation of tubu-
lar epithelial cells (TEC) forming multiple renal cysts  [1] . 
Currently there is no specific treatment for ADPKD oth-
er than supportive care, and dialytic treatment or renal 
transplantation when patients have reached end-stage re-
nal disease. Because ADPKD progresses slowly, there is a 
window of opportunity to treat the disease by using ther-
apeutical principles which retard cystic expansion, thus 
preventing the development of end-stage renal disease.
 The mammalian target of rapamycin (mTOR), an 
atypical serine/threonine kinase, is a central controller of 
cell growth and proliferation  [3] . The mTOR pathway is 
not activated in normal adult kidneys but is aberrantly 
activated in kidneys of different rodent models for poly-
cystic kidney disease (PKD) as well as in cyst-lining cells 
in human ADPKD  [4, 6] . Rapamycin (also termed siroli-
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 Abstract 
 Background/Aims: Rapamycin inhibits cyst growth in poly-
cystic kidney disease by targeting the mammalian target of 
rapamycin (mTOR). To determine if this is a class effect of the 
mTOR inhibitors, we examined the effect of everolimus,
the analogue of rapamycin, on disease progression in the 
Han:SPRD rat model of polycystic kidney disease.  Methods: 
Four-week-old male heterozygous cystic (Cy/+) and wild-
type normal (+/+) Han:SPRD rats were administered everoli-
mus or vehicle (3 mg/kg/day) by gavage for 5 weeks. Kidney 
function and whole-blood trough levels of everolimus were 
monitored. After treatment kidney weight and cyst volume 
density were assessed. Tubule epithelial cell proliferation 
was assessed by BrdU staining.  Results: Everolimus trough 
levels between 5 and 7   g/l were sufficient to significantly 
reduce kidney and cyst volume density by approximately 50 
and 40%, respectively. The steady decrease of kidney func-
tion in Cy/+ rats was reduced by 30% compared with vehicle-
treated Cy/+ rats. Everolimus treatment markedly reduced 
the number of 5-bromo-2-deoxyuridine-labeled nuclei in 
cyst epithelia. Body weight gain and kidney function were 
impaired in everolimus-treated wild-type rats.  Conclusion: 
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mus) is a specific inhibitor of mTOR with strong anti-
proliferative properties. Rapamycin is clinically used to 
prevent organ rejection in renal transplant patients. Fur-
thermore, cardiac stents coated with rapamycin abolish 
intrastent neointimal proliferation. Recently we and oth-
ers have shown that rapamycin when administered intra-
peritoneally or through the drinking water successfully 
retards disease progression in different rodent models of 
PKD  [5–7] . Relatively low blood level of rapamycin de-
creased cyst volume density by approximately 20% in the 
Han:SPRD rat, a model for PKD  [6] .
 Everolimus [40-O-(2-hydroxyethyl)-rapamycin], also 
called RAD001, is a macrolide antibiotic that binds to the 
intracellular protein FKBP and thereby inhibits mTOR 
activity  [8] . It is an orally active derivative of sirolimus 
(rapamycin), with a hydrophilic 2-hydroxyethyl chain at 
position 40  [9] . Compared to rapamycin, everolimus has 
a shorter half-life and a higher biological availability  [10] . 
Everolimus is also used as an immunosuppressive drug 
in organ transplantation. Currently an ongoing clini-
cal trial is testing whether everolimus (Certican  ; 
NCT00414440) whole-blood trough levels between 3 and 
8   g/l halt disease progression in human ADPKD. Sur-
prisingly, it is not known if everolimus halts disease pro-
gression in PKD animal models.
 Han:SPRD  rats represent one of the most commonly 
used rodent models of PKD, phenotypically resembling 
human ADPKD  [11] . To determine whether the observed 
cyst inhibition is rapamycin-specific or if this is a class 
effect of the mTOR inhibitors, we examined the effect of 
everolimus on renal functional loss and cyst progression 
in the Han:SPRD rat model of ADPKD. To achieve con-
sistent blood levels of everolimus, we employed daily ga-
vage feeding in this study.
 Materials and Methods 
 Animals 
 This study was conducted in heterozygous cystic (Cy/+) and 
wild-type normal (+/+) rats. Only male rats were used, since cysts 
develop more rapidly in male than female rats  [12] . The Han:SPRD 
rat colony was established in our animal facility from a litter which 
was obtained from the Rat Resource and Research Center (Colum-
bia, Mo., USA). The study protocol was approved by the regulatory 
commission for animal studies, a local government agency. Rats 
had free access to tap water and standard rat diet.
 Study Drug 
 Everolimus microemulsion (20 mg/g) and vehicle microemul-
sion were kindly supplied by Novartis (Basel, Switzerland) and 
stored at –20  °  C. Everolimus and vehicle were diluted with tap 
water before oral administration.
 Experimental Protocol 
 Male Cy/+ and +/+ rats were weaned and then treated with
3 mg/kg/day everolimus (Cy/+, n = 8; +/+, n = 10) or vehicle (Cy/+, 
n = 4; +/+, n = 11) at 4 weeks of age. Everolimus was administered 
once daily by gavage feeding for 5 weeks (day 0 to day 35) at a vol-
ume of 2 ml/day. The dose of everolimus administered was ad-
justed daily according to the rat body weight.
 Tail blood was obtained from rats on days 0, 17 and 36. Whole 
blood for everolimus levels and plasma for blood urea nitrogen 
(BUN) were stored at –20  °  C. Blood everolimus levels and BUN 
were analyzed later by kinetic color test and HPLC mass spectros-
copy at the Institute for Clinical Chemistry, University Hospital 
(Zürich, Switzerland). Everolimus 6-hour levels were measured 
on day 17 and everolimus trough levels (24-hour level) on day 36. 
BUN concentrations were determined on days 0, 17 and 36. 
 For the assessment of cell proliferation 5-bromo-2-deoxyuri-
dine (BrdU) (Sigma, St. Louis, Mo., USA) was injected subcutane-
ously (20 mg/kg/day BrdU in 0.9% NaCl) in 3 rats per group on 
days 33, 34 and 35.
 After the 5-week treatment the rats were anesthetized with iso-
flurane, and kidneys were excised, decapsulated and weighed.
 For histologic examinations, 3 rats per group were anesthe-
tized by an intraperitoneal injection of pentobarbital (100 mg/kg 
body weight) and fixed by vascular perfusion  [13] . The fixative 
contained 3% paraformaldehyde (PFA), 0.01% glutardialdehyde 
and 0.5% picric acid, dissolved in a 3:  2 mixture of 0.1  M cacodyl-
ate buffer (pH 7.4, added with sucrose, final osmolality 300 mos-
mol) and 4% hydroxyl ethyl starch (Fresenius Kabi, Bad Hom-
burg, Germany) in 0.9% NaCl. The kidneys were fixed for 5 min 
and then rinsed by vascular perfusion with 0.1  M cacodylate
buffer for 5 min.
 Histology 
 Two- to three-millimeter-thick mid-transversal rat kidney 
slices were dehydrated in ethanol series, embedded in paraffin 
and subjected to periodic acid-Schiff staining for cyst volume 
density determination.
 Cyst volume density was assessed by morphometry, using the 
method of point counting  [14] . For morphometry 4–6 micro-
graphs were obtained for 1 section per rat as described before  [6] . 
The pixel size of the micrographs was 1,300  ! 1,030 (1.34   m/
pixel). An orthogonal grid with a line spacing of 150 pixels was 
used. The reviewer who performed the morphometry was blinded 
to experimental groups.
 Anti-BrdU clone 3D4 (BD Biosciences Pharmingen, San Die-
go, Calif., USA) was mouse monoclonal. For the detection of 
BrdU, 2-mm-thick slices of perfusion-fixed kidney were frozen in 
liquid propane cooled down to –196  °  C by liquid nitrogen and cut 
into 4-  m-thick cryostat sections. The cryostat sections were mi-
crowaved for 10 min in 0.01  M citrate buffer at pH 6.0. After pre-
treatment in 5% normal goat serum in PBS, the cryostat sections 
were incubated overnight in a humidified chamber at 4  °  C with 
the primary antibody, diluted in PBS-1% BSA. Binding sites of the 
primary antibodies were revealed with a fluorescein-isothiocya-
nate-conjugated goat anti-mouse IgG (Jackson ImmunoResearch 
Laboratories, West Grove, Pa., USA). For staining of brush border 
in the proximal tubule, rabbit-anti-mXT2 [targeting the 18 amino 
acid peptide antigen NH 2 -MAQ ASG  MDP LVD IED ERC-
COOH; affinity purified, dilution  1:  200] was applied and fol-
lowed by the secondary antibody Alexa Fluor 594 donkey anti-
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rabbit IgG (1:  1,000; Molecular  Probes, Portland, Oreg., USA)  [15] . 
For control of unspecific binding of secondary antibodies we 
made control incubations by omitting the primary antibody. 
These control experiments were negative. The sections were 
placed on coverslips, using DAKO-Glycergel (Dakopatts), to 
which 2.5% 1,4-diazabicyclo[2,2,2]-octane (DABCO; Sigma, St. 
Louis, Mo., USA) was added as fading retardant. Sections were 
studied by epifluorescence with a Polyvar microscope (Reichert 
Jung, Vienna, Austria). The fluorescence for Alexa Fluor 594 and 
fluorescein isothiocyanate were recorded separately using U1 and 
B2 filter modules, respectively. Overlays of the 3 channels were 
performed with the Image-Pro software. Images were acquired 
with a charge-coupled device camera (Visicam 1280, Visitron 
Systems, Puching, Germany) and processed by Image-Pro and 
Photoshop software.
 Statistical Analyses 
 Statistical analyses were performed by one-way ANOVA with 
the Newman-Keul post hoc test using GraphPad Prism 4 soft-
ware. All data are expressed as means  8 SEM and p  ! 0.05 was 
considered as statistically significant.
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 Results 
 Blood Level of Everolimus 
 The everolimus 6-hour and 24-hour trough whole-
blood levels were 27.7  8 3.1 and 5.8  8 0.4   g/l in +/+ 
rats, and 20.7  8 2.4 and 7.1  8 1.2   g/l in Cy/+ rats ( fig. 1 ). 
The lower everolimus blood levels at 6 h in Cy/+ rats 
(25%, p  ! 0.05) compared with +/+ rats suggest a differ-
ence in absorption and/or metabolism. The difference of 
everolimus trough levels between +/+ and Cy/+ rats was 
not significant.
 Everolimus Treatment Retarded the Increase of 
Kidney Weight 
 The once a day administration of everolimus by ga-
vage feeding for 5 weeks reduced 2-kidney weight in Cy/+ 
Han:SPRD rats by 53% (p  ! 0.001;  fig. 2 A).  Figure 2 B 
shows that everolimus reduced the 2-kidney/total body 
weight ratio by 39% (p  ! 0.001) in Cy/+ rats. Everolimus 
treatment had no effect on the 2-kidney/total body weight 
of +/+ rats. Everolimus treatment lowered body weight 
gain in the same magnitude in +/+ (n = 10) and Cy/+ 
(n = 8) rats. The mean weight difference was –24% for
+/+ (p  ! 0.001) and –23% for Cy/+ rats (p  ! 0.001) on day 
36 compared to vehicle-treated rats ( fig. 3 ). These results 
 Fig. 4. Everolimus decreases the renal cyst growth in Cy/+ rats. Representative paraffin-embedded kidney sec-
tions of wild-type/vehicle (+/+;  A ), heterozygous/vehicle (Cy/+;  B ), heterozygous/everolimus rat (Cy/+;  C ).  D Cyst 
volume density (CVD) of Cy/+ rat was reduced by 48% after everolimus treatment.  * p  ! 0.001 Cy/+ with ve-
hicle versus Cy/+ with everolimus group. Bar scale: 1 mm. 
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show that everolimus treatment inhibited body weight 
and kidney weight gain in +/+ and Cy/+ rats. However, 
the effect on Cy/+ kidney weight was more pronounced 
than on +/+ kidney weight.
 Everolimus Inhibited the Increase of Renal Cyst Size 
and the Number of Proliferating Epithelial Cells 
 Histological examination was performed on Han:
SPRD rat kidneys by periodic acid-Schiff staining.  Figure 
4 B shows that renal cysts predominantly exist in the cortex 
and to a lesser extent in the outer medulla. No cysts were 
found in the inner medulla in Cy/+ rats at 9 weeks of age. 
The everolimus treatment did not change the histology 
pattern in Cy/+ rats but it significantly reduced cyst den-
sity by 48% (p  ! 0.001) in Cy/+ rats ( fig. 4 C, D).
 We then examined the effect of everolimus treatment 
on cyst epithelial cell proliferation by BrdU application in 
everolimus- or vehicle-treated Cy/+ rats (n = 3) on days 
33, 34 and 35.  Figure 5 A demonstrates that BrdU pre-
dominantly labeled cyst epithelial cells in vehicle-treated 
Cy/+ rats. Everolimus strikingly reduced the number of 
BrdU-labeled TEC in the cortex ( fig. 5 B) and in the outer 
medulla (not shown) of Cy/+ rats.
 Renal Functional Deterioration Was Stabilized in 
Everolimus-Treated Cy/+ Rats 
 The reduction of cyst growth and kidney weight by 
everolimus was accompanied by a significant ameliora-
tion of renal functional loss on day 36. The BUN level was 
31% (p  ! 0.001) lower in Cy/+ rats compared with vehicle-
 Fig. 5. Proliferating cells are reduced after everolimus treatment 
in Cy/+ rats. BrdU (green fluorescence) is incorporated in prolif-
erating cells. BrdU-positive cells were evaluated in vehicle-treated 
Cy/+ rats ( A ) and everolimus-treated Cy/+ rats ( B ). The brush 
border of the proximal tubule is shown by a red fluorescence with 
an antibody against XT-2. More normal tubule structures and 
fewer BrdU-positive cells are visible in everolimus-treated Cy/+ 
rats compared to vehicle-treated Cy/+ rats. Bar scale: 100   m. 
 Fig. 6. Everolimus retards loss of renal function in Cy/+ rats. BUN 
as a parameter of renal function was monitored on days 0, 17 and 
36. The steady increase of BUN levels was reduced by 31% in Cy/+ 
rats after 5 weeks of everolimus treatment.  * * p  ! 0.001 Cy/+ with 
vehicle versus Cy/+ with everolimus group.  * p  ! 0.05 +/+ with 
everolimus versus +/+ with vehicle group. 
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treated Cy/+ rats ( fig. 6 ). Everolimus treatment did not 
completely prevent the renal functional deterioration in 
Cy/+ rats, as BUN levels in everolimus-treated Cy/+ rats 
were 28% (p  ! 0.01) higher than in vehicle-treated +/+ 
rats. Everolimus treatment also resulted in a 20% (p  ! 
0.05) increase of BUN level in +/+ rats.
 Discussion 
 There is current experimental evidence indicating 
that mTOR is out of control in inherited PKD. Aberrant 
signals through mTOR have been shown in different ro-
dent models of PKD and in human ADPKD  [4, 5] . Here 
we show that mTOR inhibition with everolimus efficient-
ly retarded the development of renal cysts and amelio-
rated kidney function in Han:SPRD rats. These results 
extend previous studies with the mTOR inhibitor rapa-
mycin, which also slowed the progression of PKD in the 
same rat model. Both mTOR inhibitors efficiently retard-
ed disease progression, suggesting that the observed ef-
fects represent a class effect of mTOR inhibition.
 Rapamycin and its analogue everolimus are both clin-
ically used as immunosuppressants and approximately 
similar whole-blood drug levels are effective in prevent-
ing allograft rejection in rats and humans  [16, 17] . In our 
previous study, relatively low rapamycin whole-blood 
levels (from 0.5 to 1.9   g/l) led to reduced BUN values 
after 1 month (by –19%) and prevented cyst growth (by 
–18%) after 3 months of treatment. Compared to that, 
moderately higher everolimus whole-blood trough levels 
(between 5 and 7   g/l) reduced BUN and cyst growth ap-
proximately 3-fold more than rapamycin, pointing to a 
profound dose effect of mTOR inhibition on cystic kid-
ney disease progression. The bioavailability of oral rapa-
mycin is low but increases markedly when given intra-
peritoneally. In the study of Tao et al.  [5] the administra-
tion of rapamycin (0.2 mg/kg/day) intraperitoneally for 5 
weeks in Han:SPRD rats reduced BUN (by –34%) and 
cyst volume density by (–40%). The rapamycin blood lev-
els were not reported in their study, but the treatment was 
comparably effective in halting disease progression as 
everolimus treatment. Notably, Tao et al. also stated a sig-
nificant reduction of body weight gain. In contrast, low 
trough level of rapamycin did not cause a significant body 
weight loss in our previous study.
 Interestingly, treatment for 5 weeks with everolimus 
also caused a slight deterioration of renal function in nor-
mal +/+ rats, as shown by increasing BUN levels. It has 
been proposed that rapamycin or everolimus can pro-
mote glomerular lesions and impair TEC regeneration in 
certain conditions  [18–20] . Like rapamycin, everolimus 
can also impair renal function  [21] . In agreement with 
our study, it has been shown by others that 1 week of 
everolimus treatment by gavage feeding with a similar 
dosage (3 mg/kg/day) impaired renal function, in normal 
rats on a low-salt diet  [21] . Furthermore, higher-dose 
(3 mg/kg/day) as opposed to a lower-dose (0.3 mg/kg/
day) everolimus treatment worsened glomerular injury 
in a rat model of glomerulonephritis, suggesting again 
that everolimus could impair renal functions dose-de-
pendently  [22] . In our previous study the lower trough 
level of rapamycin did not increase BUN levels in +/+ rats. 
In future clinic studies using everolimus, the dosage 
needs to be adjusted carefully to balance the beneficial 
and adverse effects of everolimus in human ADPKD pa-
tients.
 BrdU staining revealed that the number of proliferat-
ing renal epithelial cells was reduced by everolimus treat-
ment. The same observation was made by Tao et al.  [5] 
by using proliferating cell nuclear antigen staining in 
Han:SPRD rats. The effect of mTOR inhibitors on TEC is 
also demonstrated by the finding that rapamycin severe-
ly impairs  the recovery from delayed graft function in 
patients who received a renal transplant and were treated 
 with rapamycin  [19, 20] . Rapamycin decreases the prolif-
eration of TEC, and a hallmark of PKD is aberrant pro-
liferation of renal epithelial cells  [23] . Therefore, the ma-
jor effect of mTOR inhibition in PKD could be the inhibi-
tion of renal tubular cell proliferation. However, we 
conducted this study in the early stages of PKD. In later 
stages of PKD, the expansion of growing renal cysts could 
occupy and squeeze the space for normal nephrons. Oth-
er pathophysiological events such as interstitial fibrosis, 
hypoxia and angiogenesis could then emerge. Therefore, 
it would be interesting to test if mTOR inhibitors could 
exert their beneficial effect beyond antiproliferative 
mechanisms in the later stages of PKD.
 We conclude that the observed inhibitory effect on 
cyst progression with everolimus is a class effect of mTOR 
inhibitors. Everolimus could be a promising new drug to 
treat ADPKD patients.
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Abstract
Background. Remodelling of matrix and tubular basement
membranes (TBM) is a characteristic of polycystic kid-
ney disease. We hypothesized that matrix and TBM degra-
dation by metalloproteinases (MMPs) could promote cyst
formation. We therefore investigated the renal expression
of MMPs in the Han:SPRD rat model of autosomal domi-
nant polycystic kidney disease (ADPKD) and examined the
effect of sirolimus treatment on MMPs.
Methods. 5-week-old male heterozygous (Cy/+) and
wild-type normal (+/+) rats were treated with sirolimus
(2 mg/kg/day) through drinking water for 3 months.
Results. The mRNA and protein levels of MMP-2 and
MMP-14 were markedly increased in the kidneys of
heterozygous Cy/+ animals compared to wild-type +/+
as shown by RT-PCR and Western blot analyses for
MMP-2 and MMP-14, and by zymography for MMP-2.
Strong MMP-2 expression was detected by immunoperoxi-
dase staining in cystic epithelial cells that also displayed
an altered, thickened TBM. Tissue inhibitor of
metalloproteinases-2 (TIMP-2) expressionwas not changed
in Cy/+ kidneys. Sirolimus treatment leads to decreased
protein expression of MMP-2 and MMP-14 in Cy/+,
whereas MMP-2 and MMP-14 mRNA levels and TIMP-2
protein levels were not affected by sirolimus.
Conclusion. In summary, in kidneys of the Han:SPRD rat
model of ADPKD, there is a marked upregulation of MMP-
2 and MMP-14. Sirolimus treatment was associated with a
marked improvement of MMP-2 and MMP-14 overexpres-
sion, and this correlated also with less matrix and TBM
alterations and milder cystic disease.
Keywords: matrix metalloproteinases (MMPs);
polycystic kidney disease (PKD); sirolimus; tissue
inhibitors of metalloproteinases (TIMPs)
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD)
is a chronic progressive kidney disease, which is charac-
terized by cystic enlargement of both kidneys. Affected
individuals usually present in the third to fourth decade
of life hypertension, haematuria, polyuria, flank pain, and
progress to end-stage renal disease within 5–10 years after
the development of renal insufficiency [1]. The presence of
numerous fluid-filled cysts is the predominant pathological
feature of PKD. In addition to cyst formation, reorganisa-
tion of tubular basement membranes (TBM) and the devel-
opment of fibrosis within the renal interstitium are char-
acteristics of PKD, suggesting that the extracellular matrix
(ECM) is intensely remodelled [2]. Tubular epithelial cells
play an important role in the synthesis and degradation of
ECM components, which in turn play a regulatory role in
epithelial cell differentiation and growth [3,4].
Matrix metalloproteinases (MMPs) are a large family of
secreted and membrane-bound zinc-dependent endopepti-
dases, which can degrade a wide spectrum of matrix sub-
strates, and therefore represent key enzymes in the turnover
of the extracellular matrix [5–7]. Most MMPs are released
as zymogens before being activated in the extracellular
environment. However, MMP-14, a membrane-bound
metalloproteinase, is processed before its insertion into
specific plasma membrane domains. In addition to its
matrix-degrading properties, MMP-14 mediates the acti-
vation of pro-MMP-2 together with the tissue inhibitor of
metalloproteinases TIMP-2, which acts as a cofactor. Acti-
vation of pro-MMP-2 from this ternary complex is finally
accomplished by a second, non-TIMP-2-bound MMP-14
molecule [7,8]. Thus, net activation of MMP-2 depends
on local MMP-14 and TIMP-2 levels, following the gen-
eral concept that the interaction of a cell with extracellular
matrix is critically determined by the concentrations of
metalloproteinases and their natural inhibitors.
The purpose of the present investigations was to exam-
ine alterations in the expression of MMPs and TIMPs in
a rodent model of PKD, namely the Han:SPRD rat, and
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to correlate these molecules with changes in matrix and
TBM structure. In a previous work, we and others have
demonstrated that sirolimus treatment of Han:SPRD rats
markedly reduced cyst growth and improved renal his-
tology [9,10]. Here, we investigated the renal expression
of MMP-2, MMP-14 and TIMP-2 in the Han:SPRD rat
model of PKD, and examined the effect of sirolimus on the
expression of these molecules.
Subjects and methods
Animals
The study was conducted in heterozygous (Cy/+) and nor-
mal littermate control (+/+) Han:SPRD rats. Only male
rats were used since the disease progresses faster in male
compared with female rats. A colony of Han:SPRD rats
was established in our animal care facility from breeding
pairs that were obtained from the Rat Resource & Research
Center (Columbia, MO, USA). The regulatory commission
for animal studies, a local government agency, approved
the study protocol. The rats had free access to tap water
and a standard rat diet. Rapamycin (Rapamune R© oral so-
lution) was kindly provided by Wyeth-AHP (Schweiz) AG,
Switzerland.
Reagents
The following antibodies from Calbiochem were used
for western blot analyses: anti-MMP-2 (468–483) (Ab-3)
human (mouse), anti-MMP-14 (Ab-4) human (mouse),
anti-TIMP-2 (Ab-2) mouse mAb (67–4H11) and as sec-
ondary antibody the peroxidase goat anti-mouse IgG.
Anti-MMP-2 (Ab-3) clone A-Gel VC2 from Neomarkers
(Fremont, CA, USA) was used for immunohistochemistry.
Experimental protocol
Male Cy/+ (n = 6) and +/+ (n = 4) rats were weaned
and were then treated at 5 weeks of age (n = 10) with
2 mg/kg/day sirolimus, as described previously [9]. Addi-
tional male Cy/+ (n = 4) and +/+ rats (n = 3) were not
treated and served as controls. The drug was administered
in the form of a Rapamune R© oral solution in the drink-
ing water for 3 months. The concentration of sirolimus
(Rapamune R© oral stock solution 1 mg/ml) was adjusted
according to rat body weight. After 3 months of treatment,
the rats were anesthetized with isoflurane, the kidneys were
removed, decapsulated and snap frozen in liquid nitrogen.
Samples were stored at −80◦C.
RNA extraction
Frozen kidney tissues were homogenized in lysis buffer
(RNeasy; Qiagen), using Lysing Matrix D tubes and a
BIO101 FastPrep R© Instrument (QBiogene, Basel, Switzer-
land). The total RNA isolation (including DNase treatment)
was performed from the homogenates according to theman-
ufacturer’s instructions (RNeasy; Qiagen). All aliquots of
sampleswere stored at−70◦Cuntil use. RNAconcentration
wasmeasured by using a spectrophotometer, and the quality
was analyzed by Bioanalyzer 2100 electropherograms
(Agilent, Waldbronn, Germany).
Genechip expression analysis
Affymetrix GeneChip R© rat genome 230 2.0 arrays
were used according to the manufacturer’s instructions
(Affymetrix Inc, Santa Clara, CA). Briefly, 5 µg of total
RNA from Cy/+ and +/+ rat kidneys was used as starting
material to generate biotin-labeled cRNA samples, which
includes cDNA synthesis using oligo-dT/T7 primers,
followed by in vitro transcription (one-cycle labeling
protocol). Labeled cRNA samples (15 µg) were randomly
fragmented to 35–200 bp and hybridized on arrays for 16 h,
and arrays were washed. The fluorescent intensity emitted
by the labeled target was measured by an Affymetrix
GeneChip Scanner 3000. Finally, the hybridization images
were analyzed using Affymetrix GCOSTM 1.2
software.
Reverse transcription and real-time taqman PCR analyses
for MMP-2, MMP-14 and TIMP-2
RT and Taqman PCR analyses for MMP-2, MMP-14 and
TIMP-2 were performed as described previously [11].
Total RNA was reverse-transcribed and PCR was carried
out using TaqMan Universal PCR Master Mix (Applied
Biosystems; containing AmpliTaq Gold DNA Polymerase),
Gene Expression Assay Mix and cDNA. Real-time PCR
analyses were performed with the ABI PRISM 7500 Se-
quence Detection System (Applied Biosystems, Rotkreuz,
Switzerland), according to the instructions of Applied
Biosystems. The expression levels of the 18S subunit of
ribosomal RNA (18S rRNA) were used as a housekeeping
gene. Relative quantification of all targets was calculated
by the comparative cycle threshold method outlined by the
manufacturer (User Bulletin No. 2; Applied Biosystems).
ForMMP-2,MMP-14, TIMP-2 and 18S, assays-on-demand
gene expression products were used as described in the
manufacturer’s protocol (Applied Biosystems).
Protein extraction
A fresh ice-cold lysis buffer was prepared for protein
extraction from frozen rat kidneys. The lysis buffer con-
sisted of 50 mM Tris base, pH 7.4; 150 mM NaCl; 1%
deoxycholate; 1% SDS; and 1% Triton X-100. Immedi-
ately before use, the lysis buffer was supplemented with 1
mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and
a protease and phosphatase inhibitor cocktail. Each sam-
ple was homogenized using a Dounce homogenizer. All
aliquots of samples were stored at −70◦C until use. Protein
concentrations were determined using the BCATM Protein
Assay reagent kit (Pierce, Lausanne, Switzerland).
Zymography for MMP-2
Activity of the gelatinase MMP-2 was analyzed by gelatin
substrate zymography. Briefly, 20 µg of each sample was
loaded on a 7.5% SDS-PAGE gel containing 0.1% gelatin.
After migration, gels were first incubated for 1 h in a mix-
ture containing 2.5% Triton X-100 and 50 mM Tris/HCl
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pH 8.0, then overnight in 50 mM Tris/HCl pH 8.0, 5 mM
CaCl2, 5 µM ZnCl2. After incubation, gels were stained
with 0.4% Coomassie blue and destained with 10% acetic
acid and 50% methanol. The white bands obtained on the
gels corresponding to MMP-2 activity were analyzed by
densitometry (Scion Image Corporation) after scanning.
The Precision Plus ProteinTM Standard (Biorad, Reinach,
Switzerland) was used as molecular weight marker, and a
recombinant MMP-2 protein from OncogeneTM was used
as positive control.
Western blot analysis for MMP-2, MMP-14 and TIMP-2
Equal amounts of protein samples and a reduced load-
ing buffer were incubated for 5 min at 95◦C. Samples
were loaded on a 7.5% SDS-PAGE gel containing 40%
acrylamid and 10% SDS. After migration, the proteins of
the gels were transferred onto a supported nitrocellulose
membrane (Biorad). The blots were blocked with 5% milk
for 1 h at room temperature and were then incubated
overnight at 4◦C in a blocking buffer containingmonoclonal
rat anti-α tubulin, or monoclonal mouse anti-MMP-2, anti-
MMP-14 or anti-TIMP-2 (dilutions 1:2000, 1:100, 1:25,
1:50). Subsequently, the blots were washed in a PBS-Tween
solution and were incubated with a goat anti-mouse HRP-
conjugated secondary antibody (dilution 1:1000). Finally,
the membranes were incubated for 5 min in an enhanced
chemiluminescent (ECL+) reagent (Amersham Pharmacia
Biotech), followed by the exposure to Hyperfilm (SuperRX
Fujifilm). The molecular weight of the bands of interest
was determined by the Precision Plus ProteinTM Standard
and by recombinant MMP-2 and TIMP-2 proteins from
OncogeneTM as positive controls.
Immunohistochemical detection of MMP-2
Rat kidney slices of about 2 mm thickness were cut
immediately after the excision. The slices were fixed by
immersion for 2 h at 4◦C in 4% freshly de-polymerized
paraformaldehyde in phosphate-buffered saline (PBS), de-
hydrated through an alcohol series and embedded in paraf-
fin. For immunohistochemistry, 3 µm thick sections were
cut and rehydrated through an alcohol series. They were
microwaved for 10 min in a 0.01M sodium citrate buffer,
pH 6.0. After blocking with 5% normal goat serum, the sec-
tions were incubated overnight at 4◦C with the primary an-
tibody. A mouse monoclonal antibody against MMP-2 was
diluted 1:500. After three washes in PBS, the binding sites
of the primary antibody were revealed with the Vectastain
ABC kit (Vector Laboratories, Burlingame, CA, USA) us-
ing 3,3’-diaminobenzidine tetrahydrochloride as substrate,
according to the instructions of the supplier. The sections
were then washed in water and were counterstained with the
periodic acid-Schiff (PAS) reagent. The nuclei were stained
with haematoxylin.
Statistics
All data are expressed as means ± SD and were considered
normally distributed. Data were analyzed by applying a
t-test using the GraphPad Prism software version 4.0 for
windows (San Diego, CA, USA). The analysis of Genechip
MAS5 normalized expression values was performed using
GeneSpring 6.1.1 (Agilent, CA, USA). A t-test was car-
ried out between the group of samples belonging to the
respective conditions, and p-values <0.05 were considered
significant.
Results
Affymetrix gene chip analysis
Microarray analysis revealed an upregulation of several in-
teresting genes in the family of metalloproteinases in Cy/+
kidneys, compared to wild-type+/+ kidneys. In particular,
we found a significant upregulation of MMP-2 (3.9-fold,
P < 0.05) and MMP-14 (3.3-fold P < 0.05) in the mi-
croarrays (Figure 1A). Sirolimus treatment did not block
this upregulation (data not shown). Real-time Taqman PCR
analysis of RNA from Cy/+ and control +/+ rat kidneys
was performed to determine steady-state mRNA changes
for MMP-2, MMP-14 and TIMP-2. Figure 1B shows a sig-
nificant increase of MMP-2 mRNA (2.2-fold, P < 0.05),
of MMP-14 mRNA (2.4-fold, P < 0.05) and an unchanged
TIMP-2 mRNA level in Cy/+ rats compared with +/+
rats, thereby validating the expression data obtained from
microarray experiments.
Enhanced MMP-2 expression and activity in Cy/+ kidneys
is reduced in sirolimus-treated rat kidneys
The expression of MMP-2 protein was then analyzed by
western blot (Figure 2A), and quantified by densitome-
try (Figure 2B). Both the pro-form (72 kD) and the active
formofMMP-2 (66 kD)were detected inwild-type rats, and
these forms were not altered by treatment with sirolimus.
There was a significant increase in the expression levels
of the pro-form and the active form of MMP-2 in un-
treated heterozygous (Cy/+) vs untreated wild-type (+/+)
rats (5.08- and 3.17-fold increase, respectively; P < 0.05).
Treatment with sirolimus effectively decreased the expres-
sion of MMP-2 pro-form and active form by 3.08-fold and
2.57-fold (P < 0.05). In Cy/+ rats, respectively, compared
to untreated Cy/+ rats (Figure 2B).
Analysis of MMP-2 activity with zymography was then
performed to correlate the level of MMP-2 expression
with its activity (Figure 3). A weak activity for the 72 kD
pro-form of MMP-2 was detectable in +/+ rats; however,
a significantly stronger activity was measured in Cy/+ ani-
mals (6.65-fold increase of the pro-form activity,P< 0.01).
Activity for the 66 kD active form could not be detected
in +/+ kidneys but was detectable in Cy/+ rats. Treatment
with sirolimus was associated with a significant decrease in
the pro-MMP-2 activity (1.55-fold decrease; P< 0.01), and
the activity of the 66 kD active formwas again undetectable.
Immunohistochemical staining in Cy/+ kidneys shows
predominant tubular upregulation of MMP-2
In +/+ rats, immunohistochemistry revealed a moderate
to strong expression of MMP-2 in interstitial cells, in the
endothelia of peritubular capillaries and in the epithelium of
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Fig. 1. (A) Microarray results of increased levels of MMP-2 and MMP-14 gene expression in Cy/+ heterozygous rats compared with +/+ wild-type
rats. TIMP-2 mRNA levels were not modified. (B) Real-time TaqMan PCR analysis of MMP-2, MMP-14 and TIMP-2 gene expression in the same set
of rats confirmed the original microarray data. The results are expressed as mean ± SD. ∗P < 0.05 compared to the +/+ group, n = 4 to 6 per group.
the capsule of Bowman (Figure 4A).Most of the convoluted
part of the proximal tubule showed aweak immunolabeling.
MMP-2 was not detected in the late convoluted part, the
straight part of the proximal tubule, the whole distal tubule
and the collecting duct.
In histologically normal tubular profiles in Cy/+ rats,
the expression of MMP-2 was similar to +/+ rats (Figure
4B). In dilated tubules, there was a striking heterogeneity of
immunolabeling (Figure 4C). The expression was similar to
+/+ rats in epithelial cells that lookedmorphologically nor-
mal. In contrast, MMP-2 staining in Cy/+ was moderate to
very strong where the epithelium displayed an abnormally
developed tubular basement membrane, as revealed by
PAS staining (Figure 4D). The association between a high
expression of MMP-2 and a modified basement membrane
was found in the proximal tubule, in the capsule of Bowman
and in the distal tubule. MMP-2 was expressed in all large
cysts, mostly at a high level (Figure 4E).
Cysts in Cy/+ sirolimus-treated rats displayed similar
levels of MMP-2 as cysts of placebo-treated rats. Ex-
pression of MMP-2 was also focally observed in tubules,
which displayed thickening of the basement membrane
(Figure 4F).
Effect of sirolimus treatment on MMP-14 and TIMP-2
expression in Cy/+ kidneys
In addition to its matrix-degrading properties, MMP-14
mediates the activation of pro-MMP-2 together with the tis-
sue inhibitor of metalloproteinases TIMP-2, which acts as a
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Fig. 2. MMP-2 expression. (A)Western blot and (B) densitometry confirmed the upregulation of the pro- and active forms ofMMP-2 in Cy/+ compared
to +/+. Treatment with sirolimus decreased these levels near to those of the wild-type. Two representative samples for each group are depicted. ∗P <
0.05 compared with the untreated or treated wild-type (+/+) rats, #P < 0.05 compared with the untreated heterozygous (Cy/+) rats, n = 4 per group.
cofactor. Since MMP-14 and TIMP-2 play decisive roles in
MMP-2 activation, we hypothesized that levels of MMP-14
and TIMP-2 would correlate with the increase of MMP-2
in the Cy/+ kidneys of ADPKD rats. The expression of
MMP-14 was investigated by western blot analysis. Figure
5 shows that MMP-14 was detected in two different forms,
as reflected by the bands at 63 and 58 kD, corresponding
to the MMP-14 proform and the active form, respectively.
MMP-14 protein expression was stronger in Cy/+ com-
pared to +/+ rat kidneys (Figure 5A). Densitometry (Fig-
ure 5B) revealed a 4.55-fold and 6.35-fold increase in both
forms of MMP-14 in Cy/+ compared to +/+ rat kidneys
(P < 0.05). Sirolimus was again associated with reduced
MMP-14 protein levels (4.93-fold and 5.73-fold, respec-
tively; P < 0.05) down to levels observed in +/+ control
rats.
TIMP-2 is involved in MMP-2 activation in conjunction
with MMP-14, but can also inhibit activation of MMP-2
[12]. Three different forms of TIMP-2 were found by west-
ern blot analysis (Figure 6A). The active form of TIMP-2
at 27 kD and the bimolecular complex of TIMP-2/MMP-14
at 70 kD were not significantly higher in Cy/+ rat kidneys
compared with +/+, and were not affected by treatment
with sirolimus (Figure 6B). However, the dimeric complex
of TIMP-2 at 54 kD increased approximately 1.59-fold
(P < 0.05) when compared with the untreated +/+ rats,
and tended to be reduced (1.45-fold; non significant) in
sirolimus-treated rats. Interestingly, of all three forms, the
TIMP-2/MMP-14 complex was the least expressed; the
TIMP-2 active form had the highest overall expression level
of the three forms.
Discussion
Others and we have shown that treatment with the mTOR
inhibitors sirolimus and everolimus delays the loss of renal
function and retards cyst development in Han-SPRD rats
[9,13–15]. Here, we show that treatment of Han:SPRD rats
with sirolimus was associated with a marked improvement
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Fig. 3. (A) Zymography showed increased activities of pro- and active forms of MMP-2 (72 and 66 kDa respectively) in untreated heterozygous
(Cy/+) rats compared with untreated wild-type (+/+) rats. MMP-2 activities were not modified by sirolimus treatment in +/+, but were decreased
in Cy/+ as determined by (B) densitometry. Ctrl = purified MMP-2 antigen (Calbiochem, Switzerland) as a reference for MMP-2 identification. Two
representative samples for each group are depicted. ∗∗P < 0.01 compared with the untreated or treated wild-type (+/+) rats, #P < 0.05 compared with
the untreated heterozygous (Cy/+) group, n = 4 per group.
ofMMP-2 andMMP-14 overexpression, and this correlated
also with less matrix and TBM alterations and milder cystic
disease.
By gene array analysis, we identifiedMMP-2 andMMP-
14 as the two major MMPs, which are markedly enhanced
in Han-SPRD rat kidneys with PKD. RT-PCR analysis,
and the examination of MMP-2 and MMP-14 protein by
western blot and zymography confirmed the upregulation.
In agreement with our findings, the abnormalities in the ex-
pression of MMPs have been described for human [16,17]
and animal models of PKD [18–20]. In humans, increased
levels of MMP-2 and -9 have been preferentially localized
in tubular epithelia forming renal cysts. In animal models,
it has been demonstrated that cystic kidney tubules can
synthesize and secrete high levels of MMPs, in particular
MMP-2 and MMP-14 [19,21,22]. In contrast to our find-
ings, Schaefer et al. found a decrease of MMP-2 expression
and activity in Cy/+ rats in early stages of PKD. However,
thismay be explained by several factors. In our experiments,
we used whole kidney homogenate instead of isolated
proximal tubules because MMP-2 has been localized to the
interstitium and to the epithelial cells of all cyst-forming
nephron segments [18]. Also, our rats were at a latter stage
of disease progression. The expression of genes involved in
fibrosis and inflammation increase with age in Cy/+ rats
and further explain our finding of increased MMP-2 ex-
pression [20]. MMP-2 expression was prominent in tubular
epithelial cells lining cysts and with an altered basement
membrane. Those two features remained associated at the
different stages of cyst growth, indicating that cystogen-
esis is associated with tubular induction of MMP-2. The
parallel increase of cyst growth and expression of genes
involved in inflammation and fibrosis suggests that MMPs
may regulate collagen accumulation at sites where cystic
transformation occurs, linking the progression of cyst
formation with ECM remodelling in PKD.
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Fig. 4. Immunohistochemistry for MMP-2 in kidney sections. In wild-type (+/+), the segments S1 and S2 of the proximal (P) tubule display a weak
immunoreactivity; the segment S3 and the distal (D) tubule are negative (A). Patches of cells that produce excess amounts of basement membrane
(arrows in B and C) represent the earliest histological alteration in (B) proximal and (C) distal tubules in Cy/+ kidneys. The cells in such patches
up-regulate MMP-2. Note the sharp transition in (D) between the normal and the altered epithelium with its thickened basement membrane and its high
immunoreactivity for MMP-2. (E)MMP-2 remains abundant in the large cysts with their thin epithelia. In Cy/+ sirolimus-treated rats, MMP-2 tubular
expression is detected in cysts and focally in tubules, which displayed thickening of the basement membrane (F).
Remodelling ECM has been hypothesized as a necessary
step for cyst expansion [21]. In a study which also used the
Han:SPRD rat, treatment with the global MMP inhibitor
batimastat reduced cyst number and kidney weight [18].
Treatment of cystic mice withWAR-1 andWTACE2,MMP
inhibitors that share some degree of activity against MMP-
9 and MMP-13 slowed disease progression [23], pointing
again to an important role of MMPs in cyst formation
in PKD. Interestingly, transgenic expression of MMP-2 in
proximal tubular epithelial leads to structural alterations in
the tubular basement membrane, fibrosis and renal failure
[24].
Sirolimus is an immunosuppressant with potent antipro-
liferative effects on non-lymphoid cells.We and others have
previously shown that sirolimus effectively retards renal
cyst development in the Han:SPRD rat [9,10]. Shilling-
ford et al. have confirmed the potent anticystic effects of
sirolimus in additional animal models of PKD [13]. Inhibi-
tion of the mTOR signalling pathway with sirolimus most
likely inhibits cell proliferation in PKD via control of ribo-
somal translation.However, thismay not be the solemode of
action. The reduced MMP-2 and MMP-14 protein expres-
sion, which occurred in response to the sirolimus treatment,
was not associated with reduced mRNA levels. Sirolimus
controls gene expression at the translational level via in-
hibition of downstream protein kinases that are required
for translation of mRNAs [25]. Effectors of the mTOR
pathway are upregulated in the kidneys of Cy/+ rats, and
protein expression of MMP-2 and MMP-14 is transduced
at least in part by these effectors of the mTOR pathway
8 C. C. Berthier et al.
Fig. 5. MMP-14 protein expression. (A) Western blot analysis and (B) densitometry showed an increase of pro- and active forms of MMP-14 protein
(63 and 58 kD respectively) in the kidneys of untreated heterozygous (Cy/+) rats compared with untreated wild-type (+/+) rats. Sirolimus treatment
did not affect both MMP-14 forms in +/+ rats. MMP-14 protein levels decreased in kidneys of Cy/+ rats treated with sirolimus. Two representative
samples for each group are depicted. ∗P < 0.05 compared with the untreated wild-type (+/+), #P < 0.05 compared with the untreated heterozygous
(Cy/+) group, n = 4 per group.
in vitro [2,26]. Thus, our results indicate that MMP-2/-14
protein expression in response to sirolimus treatment is
mainly due to translational regulation, because mRNA lev-
els of neither protein show a decrease with sirolimus treat-
ment. It is unlikely that the reduction of MMP-2 andMMP-
14 in sirolimus-treated rats ismainly due to TIMP inhibition
because the active form of TIMP-2 remained unchanged.
Increased TIMP-2 expression has been shown in Cy/+ rats
by in situ hybridization, but when TIMP-2 RNA expression
was analysed in total kidney by an RNase protection assay,
no pronounced effect was seen and the favourable effect
of batimastat on cyst growth was different from TIMP-2
expression [18]. In line with this result is our finding that
sirolimus treatment did not change TIMP-2 expression. In
8-week-old Cy/+ rats, an increased expression of TIMP-2
was found in proximal tubules [22]. We cannot exclude
that in the early disease stage, locally expressed TIMP-2 is
associated with cyst development. Although in our study
we cannot prove a direct effect of sirolimus on MMP-2 and
MMP-14 expression, it is plausible that part of the benefi-
cial effects of sirolimus might be caused by inhibition of
MMPs.
Renal fibrosis is a hallmark of cystic disorder in hu-
man ADPKD [27] and in Han:SPRD rats [28]. Fibrosis
increases with the progression of disease, indicating a link
between cystogenesis and fibrogenesis. It is therefore dif-
ficult to deduce the effect of sirolimus on reduced cyst
growth from improved MMP activities, and it can either
be a consequence of the specific action of sirolimus or the
reflection of the overall improvement of the severity of the
disease. A number of recent studies show that sirolimus
has prominent therapeutic effects on various renal dis-
eases where matrix production and fibrosis are enhanced.
In a model for experimental membranous nephropathy, a
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Fig. 6. TIMP-2 protein expression. (A) Western blot analyses and (B) densitometry revealed three forms of TIMP-2: the active form (TIMP-2 free
form), the dimer TIMP-2 and the complex TIMP-2/MMP-14 are depicted by three bands of 27 kD, 54 kD and 70 kD, respectively. Whereas the two
complexes appeared to be strongly increased in heterozygous (Cy/+) kidneys, the free form was not differentially expressed compared to the wild-type
(+/+). Sirolimus treatment decreased the TIMP-2 complexed forms in +/+ and Cy/+ rats, but did not affect the levels of TIMP-2 active form. Two
representative samples for each group are depicted. ∗P < 0.05 compared with the untreated wild-type (+/+) rats, n = 4 per group.
relatively low dose of sirolimus resulted in reduced
interstitial inflammation and fibrosis [29]. Treatment
with sirolimus blunted compensatory renal hypertrophy;
a similar effect has been observed in the rat model
for hydronephrosis [30]. Sirolimus also blocked tubular
epithelial-to-mesenchymal transition, a critical step in fi-
brogenesis. These results support the hypothesis that the
beneficial effect of sirolimus is not only mediated by its
antiproliferative effect but by multiple mechanisms.
In conclusion, MMP-2, MMP-14 and TIMP-2 are dys-
regulated in the Han:SPRD rat model of ADPKD. The ac-
tivation of MMP-2 and MMP-14 is markedly suppressed in
vivo by the treatment of Han:SPRD rats with sirolimus, and
this is correlated with less matrix and TBM alterations and
milder cystic disease.
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Abstract
Background: Currently there is no effective treatment available to retard cyst growth and to
prevent the progression to end-stage renal failure in patients with autosomal dominant polycystic
kidney disease (ADPKD). Evidence has recently been obtained from animal experiments that
activation of the mammalian target of rapamycin (mTOR) signaling pathway plays a crucial role in
cyst growth and renal volume expansion, and that the inhibition of mTOR with rapamycin
(sirolimus) markedly slows cyst development and renal functional deterioration. Based on these
promising results in animals we have designed and initiated the first randomized controlled trial
(RCT) to examine the effectiveness, safety and tolerability of sirolimus to retard disease
progression in ADPKD.
Method/design: This single center, randomised controlled, open label trial assesses the
therapeutic effect, safety and tolerability of the mTOR inhibitor sirolimus (Rapamune®) in patients
with autosomal dominant polycystic kidney disease and preserved renal function. The primary
outcome will be the inhibition of kidney volume growth measured by magnetic resonance imaging
(MRI) volumetry. Secondary outcome parameters will be preservation of renal function, safety and
tolerability of sirolimus.
Discussion: The results from this proof-of-concept RCT will for the first time show whether
treatment with sirolimus effectively retards cyst growth in patients with ADPKD.
Trial registration: NCT00346918
Background
Autosomal dominant polycystic kidney disease (ADPKD)
is the most common hereditary cause of end-stage renal
disease (ESRD), affecting all ethnic groups worldwide,
with an incidence of 1 in 500 to 1 in 1000 [1]. ADPKD is
characterized by the progressive development of innumer-
able cysts in both kidneys, which distort the normal kid-
ney architecture and leads to a loss of renal function. The
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BMC Nephrology 2007, 8:13 http://www.biomedcentral.com/1471-2369/8/13development of renal failure is highly variable, but typi-
cally patients develop ESRD by the age of 40 to 50 years,
necessitating renal replacement therapy (RRT) and/or kid-
ney transplantation [2]. Apart from blood pressure con-
trol and symptomatic treatment of cyst bleedings and
infections there is no curative therapy for this disease [3].
PKD1 and PKD2 encode the proteins polycystin-1 and
polycystin-2 which are expressed in the kidney and func-
tion together to regulate growth and morphologic config-
uration of renal epithelial cells [4]. Mutation in PKD1
leads to a more severe phenotype of ADPKD than muta-
tions in PKD2, with ESRD occurring on average 20 years
earlier (53.4 versus 72.7 years) [5].
In ADPKD progressive cyst growth generally precedes the
development of renal insufficiency. Compensatory mech-
anisms (hyperfiltration) maintain renal function virtually
normal for decades despite continuous cyst growth. By the
time renal function starts to decline, the kidneys are usu-
ally grossly enlarged with little normal renal parenchyma
recognisable on imaging studies. Data from the consor-
tium for radiologic imaging studies of polycystic kidney
disease (CRISP) and others have shown that the rate of
kidney volume growth is a predictor of renal functional
decline and therefore kidney volume is used as surrogate
marker of disease progression especially in clinical inter-
vention trials for ADPKD [6,7]
Non-invasive radiologic methods are available to monitor
the growth rate of kidney volume. Renal ultrasound meas-
urements are operator-dependent and not precisely repro-
ducible. Unenhanced and contrast enhanced Computer
tomography (CT) scanning is reported to be an accurate
method to determine kidney volume, but it involves ion-
izing radiation and potentially nephrotoxic contrast
medium and is therefore not an ideal method in patients
with reduced kidney function needing repetitive measure-
ments [8,9]. Due to its high soft tissue contrast and the
lack of ionizing irradiation Magnetic resonance imaging
(MRI) is also considered useful to monitor kidney volume
changes in ADPKD. The analysis of sequential MRI scans
was shown to be accurate to monitor rates of kidney vol-
ume enlargement in ADPKD [7].
Sirolimus is an immunosuppressant that binds to FK
Binding Protein-12 (FKBP-12) and inhibits the activation
of the mTOR, a key regulatory kinase of growth and pro-
liferation. Sirolimus is approved for the prevention of
graft rejection following renal transplantation. Due to its
antiproliferative properties it is also used in coated stents
to prevent coronary artery restenosis after angioplasty
[10]. Furthermore it has shown clinical effectiveness in
kidney transplant recipients with Kaposi's sarcoma [11].
We have shown previously that the mTOR inhibitors
rapamycin and everolimus effectively reduce cyst growth
and loss of renal function in an experimental animal
model for PKD [12,13]. Additional studies have shown
that rapamycin is also effective in various mouse models
of polycystic kidney disease, including dominant and
recessive forms [14]. Of interest, an analysis of ADPKD
patients which received a renal transplant, revealed that
cystic kidney volumes regressed under immunosuppres-
sion with sirolimus [15]. Based on these promising results
we have designed and initiated the first clinical trial to
examine the effectiveness and safety of sirolimus in young
patients with early manifestations of ADPKD and intact
renal function.
Methods/Design
Study aim
The primary objective of the SUISSE ADPKD study is to
assess the effectiveness of sirolimus to retard kidney vol-
ume growth and to prevent the loss of renal function in
young patients with ADPKD and preserved renal function.
Patients with ADPKD and kidney volume growth that can
be documented within 6 months are randomized to treat-
ment with sirolimus 2 mg/day for 18 months (Figure 1) or
standard treatment. The secondary objectives are to follow
renal function and blood pressure and to monitor for the
occurrence of proteinuria. Safety and tolerability of
sirolimus treatment in ADPKD patients will also be
assessed.
Study design and setting
The study is a single center randomised controlled open
label trial which is open to ADPKD patients with a posi-
tive family history of ESRD due to ADPKD thereby select-
ing mostly patients with mutations in the PKD1 gene. The
study will involve 100 ADPKD-patients aged 18–40 years
with a creatinine clearance >70 ml/min. Kidney volumes
will be measured by MRI without contrast media at study
month 0 and 6. Patients with documented volume pro-
gression are randomized at a 1:1 ratio to sirolimus 2 mg/
day or standard treatment for 18 months. Recruitment has
started in May 2006 and will last until December 2007.
The study will be completed by December 2009.
Ethical considerations
Ethical approval has been obtained form the local ethics
committee of the University Hospital Zürich.
Study drug and dosing
Rapamune® (sirolimus) will be used at a fixed dose of 2
mg daily to achieve sirolimus through levels between 4–
10 µg/L. By using this rather low dose of sirolimus as
monotherapy we expect a low incidence of sirolimus-
related adverse events. The dose will be reduced or with-
held in case of a through level exceeding 10 µg/l, elevatedPage 2 of 6
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penia (< 100'000/mm3), leukopenia (< 3'000/mm3) or
serious sirolimus-associated toxicity.
Study drug adherence
Adherence to the prescribed study drug will be assessed by
using the Medication Event Monitoring V Track-Cap Sys-
tem (MEMS®, Aardex, Ltd., Zug, Switzerland) during the
complete treatment period. The MEMS® assesses the med-
ication adherence reliably and sensitive as a period with a
lack of medication bottle opening documentation, repre-
senting most likely an episode of non-adherence [16,17].
The system monitors electronically the date and time of
the medication bottle opening. We will measure 1) treat-
ment adherence as the proportion of medication vial caps
opened in a given month relative to the prescribed doses
for that month, 2) dosing adherence as the percentage of
days with correct dosing and 3) drug holidays, as the
number of periods without drug intake that exceeded 48
hours.
Identification of eligible patients
Study participation is offered to all eligible patients with
ADPKD. ADPKD patients suffering from advanced renal
failure including dialysis patients and transplant recipi-
ents treated at our clinic are informed about the study and
screening for ADPKD is offered to their relatives. All neph-
rology clinics and dialysis units in Switzerland have been
informed and information material (print and in the
internet [18]) for study participants and health profes-
sionals has been provided. Potential study participants are
invited for a screening visit including medical history,
physical examination, renal ultrasonography and blood
and urine analyse.
Male or female ADPKD patients aged 18 to 40 years with
a creatinine clearance ≥ 70 ml/min are eligible for the
study if they exhibit a kidney volume progression over the
observational pre-randomisation period of 6 months. The
diagnosis of ADPKD is based on ultrasonographic diag-
nostic criteria in patients with a family history of poly-
cystic kidney disease [19]. In patients with negative family
history, proof of a mutation in the PKD1 or PKD 2 genes
is required for inclusion (sequencing analysis; Athena
Flow chart of SUISSE ADPKD studyigure 1
Flow chart of SUISSE ADPKD study.Page 3 of 6
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inclusion and exclusion criteria are given in table 1 and 2.
Randomization and study blinding
Patients are randomized at a one to one ratio to sirolimus
or standard treatment alone. The randomisation list has
been generated by a biostatistics unit which is independ-
ent of the study team using a permuted blocks design with
a random block size of 4 and 6 to guarantee a balanced
allocation. The randomisation codes are kept in sealed
sequentially numbered opaque envelopes and are not
opened until two MR scans within 6 months have shown
an enlargement of the total kidney volume of ≥ 2 %.
Primary outcome
The primary objective of the SUISSE ADPKD study is to
determine the effect of sirolimus treatment on kidney vol-
ume enlargement in ADPKD patients with preserved renal
function. Patients with documented kidney volume
growth in the last six months will be randomized to
sirolimus or standard treatment. Kidney volume will be
measured 6 and 18 months after randomization and the
percent annual growth of the combined (left and right)
kidney volume will be calculated.
Secondary outcome
Absolute kidney volume growth from inclusion to month
18 will be assessed as a secondary outcome. Other second-
ary objectives are to compare blood pressure, renal func-
tion and proteinuria in patients with sirolimus or
standard treatment and to assess safety and tolerability of
sirolimus treatment. New onset or progression of arterial
hypertension might reflect disease progression of ADPKD
or a potential adverse drug effect and will be assessed
comparing the change of blood pressure and the change
of antihypertensive drug dosage during follow up. Renal
function will be assessed by using estimation equations
(Cockcroft-Gault and cystatin C) as well as measured cre-
atinine clearance determined by 24-hour urine collection.
Proteinuria will also be measured by 24-hour urine collec-
tion. The frequency and severity of all reported adverse
events will be recorded, including laboratory abnormali-
ties such as anemia, thrombocytopenia and hyperlipi-
demia.
Magnetic resonance imaging
All individuals undergo MR imaging of the kidneys using
a 1.5 Tesla scanner. For signal reception in all examina-
tions an 8-channel anteroposterior phased-array surface
coil (torso array coil) is placed around the patient and
covers the entire kidneys. The imaging protocol includes
unenhanced sequences only. In order to get an overview
of the extent of the cystic disease of the kidneys a coronal
single shot fast spin echo (SSFSE) sequence is acquired in
breath hold technique. The MR imaging parameters of
this sequence are as follows: repetition time (TR) msec/
echo time (TE) msec 1349/90.1; field of view 48 × 48 cm;
acquisition matrix 384 × 224; section thickness 4 mm; no
interslice gap. Based on this coronal sequence the transax-
ial sequences are planned. The transaxial sequences con-
sists of two breath hold T1-weighted fast spoiled gradient
echo (FSPGR) sequences (TR msec/TE msec = 85/1.4)
with two different slice thicknesses (3 and 4 mm, respec-
tively). Other parameters of the T1-weighted gradient-
echo pulse (GRE) sequences are: field of view 48 × 48 cm,
matrix 256 × 160; no interslice gap. In addition a transax-
ial T2-weighted fast spin echo (FSE) sequence with respi-
ratory triggering is performed (TR msec/TE msec = 17143/
102.8; field of view 48 × 48 cm, matrix 256 × 160, thick-
ness 3 mm; no interslice gap). To measure the kidney vol-
umes the transaxial breath hold T1-weighted FSPGR
sequence with a slice thickness of 3 mm is primarily used.
In case of a more advanced disease with large polycystic
kidneys and/or when respiratory artefacts are present the
volume measurements are either performed on the
transaxial breath hold T1-weighted FSPGR sequence with
a slice thickness of 4 mm or on the transaxial T2-weighted
FSE sequence. Once one of these sequences is chosen the
Table 2: Study exclusion criteria
• Female patient of childbearing potential who is unwilling to use 
effective means of contraception
• Increased liver enzymes (2-fold above normal values)
• Hypercholesterolemia (fasting cholesterol > 8 mmol/l) or 
hypertriglyceridaemia (> 5 mmol/l) not controlled by lipid lowering 
therapy
• Granulocytopenia (white blood cell < 3,000/mm3) or 
thrombocytopenia (platelets < 100,000/mm3)
• Infection with hepatitis B or C, HIV
• History of malignancy
• Mental illness that interferes with the patient ability to comply with 
the protocol
• Drug or alcohol abuse within one year of baseline
• Co-medication with strong inhibitor of CYP3A4 and or P-gp like 
voriconazole, ketoconazole, diltiazem, verapamil, erythromycin or 
with a strong CYP3A4 and or P-gp inductor like rifampicin
• Known hypersensitivity to macrolides or Rapamune®
• Patients who are unwilling or unable to give informed consent
Table 1: Study inclusion criteria
• Age 18 to 40 years
• GFR ≥ 70 ml/min (Cockcroft - Gault formula)
• Diagnosis of ADPKD:
❍ Positive family history for ADPKD
■ patients < 30 years: ≥ 2 cysts in either kidney
■ patients ≥ 30 years: ≥ 2 cysts in each kidney
❍ Negative family history for ADPKD but sonographically cystic 
kidney disease: proof of a mutation in the PKD1 or PKD2 gene is 
required (Athena Diagnostics, Inc., Worcester, MA, USA)
• Documented kidney volume enlargement (MRI volumetry)
• Signed informed consentPage 4 of 6
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following MR imaging sessions.
Renal volume measurements
Two independent trained observers perform a manual
segmentation of both kidneys for each patient. To prevent
bias, the observers are blinded to all clinical and radiolog-
ical data, their first measurements and the results of the
other observer. The measurements are performed in ran-
dom order. Blinding is performed with regard to patients
and the different time points when imaging has been
obtained. Manual segmentation is performed electroni-
cally on an interactive workstation (Advantage Windows
Workstation; GE Medical Systems Europe, Buc, France).
Each kidney is assessed separately. On each section, the
outlines of the kidney are manually drawn by using the
computer mouse. The vessels and the ureter in the area of
the renal hilum are excluded from manual volumetric
marking. The volume corresponding to each outline is
obtained by multiplying the area of the outline by the sec-
tion thickness. The total volume of the kidney segments is
obtained by summing the volume of each section. The
manufacturer's software automatically calculates the total
volume after drawing the outlines of the kidney on all sec-
tions. Mean values of the measurements performed by the
two independent observers will be used for analysis. In
case of a large disagreement, both observers will repeat
measurement.
Data collection
Data will be collected into a web-based data base designed
to capture all visit information including medical history,
results form laboratory analysis and adverse events. Base-
line data and ongoing data collection as outlined in table
3 will be obtained.
Patient follow-up procedures
Study duration for all patients will be 24 months in total,
consisting of a 6 months pre-randomisation observa-
tional period and 18 months follow up after randomisa-
tion (Figure 1). Four main study visits including kidney
MRI and 24 h urine collection will take place at baseline,
month 6, 12 and 24. Randomisation and inclusion in the
study takes place after evaluation of kidney volume
growth from baseline to month 6 within 2 weeks after the
second MRI. Three additional visits including clinical
assessment and blood and urine chemistry will take place
at month 9, 15 and 18. Patients in the treatment arm will
have four extra visits at week 2, 4, month 1 and 2 after ran-
domisation to allow for blood level monitoring and
potential dose adjustment of the study medication.
Patients without volume progression during the pre-ran-
domisation period will be followed by MRI for additional
6 months and enrolled if kidney volume enlargement is
detectable.
Study withdrawal
Patients will be censored and withdrawn from follow-up
at their request. Patients will also be censored if they are
not randomized after the pre-randomization observation
period.
Statistical analysis
Principal analysis will be undertaken using an intention-
to-treat approach. A secondary on-treatment analysis will
also be performed. The annual percent change in kidney
volume will be determined by regressing the log trans-
formed total kidney volume at month 6, 12 and month 24
against time for each patient through the least squares
method. Mean annual decline of renal function will be
calculated by regressing GFR or creatinine clearance
against time. All primary and secondary end point varia-
bles will be compared using a two-sided α-level of 0.05.
To account for possible baseline imbalances, a secondary
analysis will be performed in which comparison of treat-
ment groups for all endpoints will be adjusted for prede-
fined covariates using multiple regressions. The
predefined covariates are age, sex, presence of hyperten-
sion, medication with angiotensin converting enzyme
inhibitors or angiotensin receptor blockers, baseline total
kidney volume and percentage kidney growth during the
pre-randomisation period.
Table 3: Baseline and ongoing data collection
Baseline data and follow-up data at month 6, 12 and 24
MRI kidney volumetry
Creatinine clearance and estimated GFR (Cockcroft-Gault)
Proteinuria (24-hour urine and spot urine)
Physical examination and vital signs
Laboratory tests
Haematology/Biochemistry
Lipid profile
Sirolimus trough level
Pregnancy test1
Serological testing for hepatitis B, C and human immunodeficiency 
virus (HIV)1
MEMS® check
Adverse events and concomitant therapy
Follow-up data every 3 months
Serum creatinine
Proteinuria (spot urine)
Physical examination and vital signs
Laboratory tests
Haematology/Biochemistry
Lipid profile
Sirolimus trough level
Adverse events and concomitant therapy
1Only at baseline and month 24Page 5 of 6
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In a large cohort of ADPKD patients, the mean annual kid-
ney volume growth rate was 5.27% ± 3.92% (SD)[7].
Because patients with lack of progression during the pre-
randomisation period will be excluded from our study, we
expect to select for a higher progression rate in our study
population. Due to a shorter observation interval com-
pared to the mentioned observational study, the standard
deviation might be higher. Presuming an annual kidney
growth rate of 6% ± 4.75% (SD) in the control group, a
sample size of 40 patients per group will have 80% statis-
tical power to detect a 50% relative reduction of kidney
volume growth using a two-sided α-level of 0.05. To
account for a drop out rate of up to 20%, we plan to ran-
domise a total of 100 patients.
Discussion
The SUISSE ADPKD study seeks to determine if sirolimus
halts kidney volume growth in patients with ADPKD early
in the disease course. Study participation is restricted to
young patients with preserved kidney function because
any effective treatment of ADPKD needs to be started early
in the course of the disease to have an impact on long
term kidney function. Our trial is the first clinical study
addressing this question. If sirolimus treatment can
reduce or stop volume growth in patients with main-
tained kidney function and prior documented kidney vol-
ume progression, these ADPKD patients could benefit the
most from a treatment with an anti-proliferative agent like
sirolimus. Similar studies using specific mTOR inhibitors
to halt disease progression have been announced by oth-
ers (Mayo Clinic, USA; Certican® trial, Novartis, Ger-
many). We anticipate that sirolimus might be an effective
therapeutic option for ADPKD patients that are prone to
progress to end-stage renal disease.
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